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ABSTRACT
Multiplicity issues arise prevalently in a variety of situations in clinical trials and
statistical methods for multiple testing have gradually gained importance with the
increasing number of complex clinical trial designs. In general, two types of multiple
testing can be performed (Dmitrienko et al., 2009): union-intersection testing (UIT)
and intersection-union testing (IUT). The UIT is of the interest in this dissertation.
Thus, the familywise error rate (FWER) is required to be controlled in the strong
sense.
A number of methods have been developed for controlling the FWER, including
single-step and stepwise procedures. In single-step approaches, such as the simple
Bonferroni method, the rejection decision of a hypothesis does not depend on the
decision of any other hypotheses. Single-step approaches can be improved in terms of
power through stepwise approaches, while also controlling for the desired error rate.
vi
Besides, it is also possible to improve those procedures by a parametric approach. In
the first project, we developed a new and powerful single-step progressive parametric
multiple (SPPM) testing procedure for correlated normal test statistics. Through
simulation studies, we demonstrate that SPPM improves power substantially when
the correlation is moderate and/or the magnitude of effect sizes are similar.
Group sequential designs (GSD) are clinical trials allowing interim looks with the
possibility of early terminations due to efficacy, harm or futility, which can reduce the
overall costs and timelines for the development of a new drug. However, repeated
looks of data also have multiplicity issues and could inflate the type I error rate.
The proper treatments to the error inflation have been discussed widely (Pocock,
1977), (O’Brien and Fleming, 1979), (Wang and Tsiatis, 1987), (Lan and DeMets,
1983). Most literature about GSD focuses on a single endpoint. GSD with multiple
endpoints however, has also received considerable attention. The main focus of our
second project is a GSD with multiple primary endpoints, in which the trial is to
evaluate whether at least one of the endpoints is statistically significant. In this
study design, multiplicity issues arise from repeated interims and multiple endpoints.
Therefore, the appropriate adjustments must be made to control the Type I error rate.
Our second purpose here is to show that the combination of multiple endpoint and
repeated interim analyses can lead to a more powerful design. Via the multivariate
normal distribution, a method that allows for simultaneously consideration of interim
analyses and all clinical endpoints was proposed. The new approach is derived from
the closure principle, thus it can control type I error rate strongly. We evaluate the
vii
power under different scenarios and show that it compares favorably to other methods
when correlation among endpoints is non-zero.
In the group sequential design framework, another interesting topic is multiple arm
multiple stage design (MAMS), where multiple arms are involved in the trial at the
beginning with the flexibility about treatment selection or stopping decisions during
the interim analyses. One of major hurdles of MAMS is the computational cost with
the increasing number of arms and interim looks. Various designs were implemented
to overcome this difficulty (Thall et al., 1988; Schaid et al., 1990; Follmann et al.,
1994; Stallard and Todd, 2003; Stallard and Friede, 2008; Magirr et al., 2012; Wason
et al., 2017), but also control the FWER with the potential inflation from the multiple
arm comparisons and multiple interim tests. Here, we consider a more flexible drop-
the-loser design allowing the safety information in the treatment selection without a
pre-specified dropping-arms mechanism and it still retains reasonable high power. The
two different types of stopping boundaries are proposed for such a design. A sample
size is also adjustable if the winner arm is dropped due to the safety considerations.
viii
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1Chapter 1
Introduction
1.1 Multiple Testing Procedures
Multiplicity issues arise prevalently in a variety of situations in clinical trials, and
statistical methods for multiple testing have gradually gained importance with the
increasing number of complex clinical trial designs. A proper treatment of multi-
plicity issues is a key component of a well-controlled clinical trial. In general, two
types of multiple testing can be performed (Dmitrienko et al., 2009). One is the
union-intersection testing (UIT), which is expressed as an intersection of a family of
hypotheses. The global null hypothesis in the UIT framework is rejected if at least
one of its individual null hypotheses is rejected. Carrying out the individual tests at
an unadjusted level leads to an inflation of the probability of rejecting the global null
hypothesis. To address this issue, an adjustment to a smaller value of significance
level for testing each individual hypothesis or a modification of testing procedure
needs to be utilized. Another type is the intersection-union testing (IUT), which,
in contrast to UIT, can be expressed as the union of a family of hypotheses. The
global null hypotheses is rejected if each of its individual null hypotheses is rejected.
2No multiplicity adjustment is necessary to control the size of the test in this testing.
Other multiple hypothesis testing can be in the form of the combination of these two
frameworks.
In union-intersection testing, the hypothesis testing can be formulated as:
H0 : ∩Kk=1µk ≤ 0(∩Kk=1Hk) v.s Ha : ∪Kk=1µk > 0(∪Kk=1H¯k),
where Hk and H¯k are the null and alternative hypotheses for the k
th test. The
probability of making at least one type I error in UIT increases with the number of
individual hypotheses tested. To solve this problem, the probability of falsely rejecting
at least one null hypothesis, which is defined as familywise error rate (FWER), is
required to be controlled in the strong sense, especially in confirmatory clinical trials.
Using the mathematical terminology, this requirement is to control the probability
of incorrectly rejecting any true hypothesis regardless of which and how may other
hypotheses are true. In the formulation, if T is the index set of true null hypotheses,
then:
supFWER = max
T
supPr(k ∈ T : Reject at least one Hk) ≤ α,
where the supremum is taken over all parameters µk in the null hypothesis space for
k ∈ T and in the alternative hypothesis parameter space for k 6∈ T , and the maximum
is taken over all index sets T . In this way, the FWER is controlled in the strong sense.
A number of methods have been developed and introduced for controlling the
FWER within the acceptance limit, including single-step and stepwise procedures. In
3single-step approaches, the unadjusted p-values are compared to the adjusted local
significance level to make the rejection decision about the global null hypothesis, or
the adjusted p-values are used to compare against the unadjusted significance level.
Bonferroni Method
The common used and simple method is Bonferroni method. The adjusted test level
alpha αk for each hypothesis is stated as αk =
α
K
. This is a conservative single-step
approach without consideration of any correlations among p-values. The alpha level
can also be split unequally, in which the adjusted alpha level is: αk = wkα, where
the weights
∑K
k=1 wk = 1. This weights wk can be determined based on the clinical
importance or the power of the kth hypothesis. This approach is called weighted
Bonferroni method.
Fisher Combination Test
Fisher combination test is usually used to test the global null hypothesis H0, in which
the Fisher statistic is:
χ2 = −2
K∑
k=1
ln(pk),
where pk is the univariate p-value for testing Hk. If the test statistics are independent,
then χ2 is distributed as a chi-square distribution with 2K degrees of freedom under
H0, and the global null H0 is rejected if χ
2 ≥ χ22K,1−α.
Single-step approaches can be improved in terms of power through stepwise
approaches, while also controlling for the desired error rate. With stepwise approaches,
some hypotheses may be retained or rejected by implication of decisions about other
4hypotheses. Stepwise approaches can be applied via step-down and step-up procedures.
A compromise between the Holm and the fixed-sequence procedures can be obtained
by the fallback procedure introduced by Wiens (Wiens, 2003).
Hommel Step-Up Procedure
A step-up procedure starts with the least significant p-value. Assume p(1), . . . , p(K) are
the sorted p-values for K hypotheses in the increasing order, with the corresponding
hypotheses as H(1), . . . , H(K). Hommel procedure follows algorithm as:
• If p(K) > α, retain H(K) and go to the next step, otherwise, reject all hypotheses
and stop.
• For k = 2, . . . , K − 1, if p(K−j+1) > (k − j + 1)α/k for j = 1, . . . , k, retain H(K−k+1)
and go to the next step. Otherwise reject all remaining hypotheses and stop.
• If p(K−j+1) > (k − j + 1)α/k for j = 1, . . . , K, retain H(1), otherwise reject it.
Hochberg Step-Up Procedure
The Hochberg procedure is another popular step-up procedure, and the decision rule
for the Hochberg procedure is as follows:
• If p(K) > α, retain H(K) and go to the next step. Otherwise reject all hypotheses
and stop.
• For k = 2, . . . , K − 1, if p(K−j+1) > α/k, retain H(K−k+1) and go to the next step.
Otherwise reject all the remaining hypotheses and stop.
• If p(1) > α/K, retain H(1). Otherwise reject it.
When only two individual hypotheses are involved in the multiple testing, Hochberg
and Hommel provides the same decisions.
5Holm Step-Down Procedure
A step-down procedure starts with the hypothesis associated with the most significant
p-value. In general, the Holm procedure examines hypotheses in the sequence as:
• If p(1) ≤ α/K, reject H(1) and go to the next step. Otherwise retain all hypotheses
and stop.
• For k = 2, . . . , K − 1, if p(k) ≤ α/(K − k + 1), reject H(i) and go to the next step.
Otherwise retain all remaining hypotheses and stop.
• If p(K) ≤ α, reject H(K). Otherwise, retain H(K).
Fallback Procedure
The fixed-sequence procedure assumes that the order in which the hypotheses are
tested is pre-specified and testing begins with the first hypothesis and is carried out
without a multiplicity adjustment if the results are significant in all preceding tests.
For the fallback procedure, the hypotheses are ordered first as well (H1, . . . , HK) and
the overall test level α is split among the hypotheses by the weights w1, . . . , wK . Then
the procedure is as follows:
• If p1 ≤ w1α, reject H1 otherwise retain it. Then go to the next step.
• For k = 2, . . . , K, test Hk at αk = αk−1 + wkα if Hk−1 is rejected and αk = wkα if
Hk−1 is retained. If pk ≤ αk, reject Hk otherwise retain it.
However, all the aforementioned methods do not take into account the joint
distribution of the test statistics; therefore they might suffer power loss when the
correlation exists. It is possible to improve the power by utilizing the known or
assumed joint distribution of the test statistics, which is called a parametric procedure.
6The most well-known parametric procedure was developed by Dunnett (Dunnett,
1955) for the dose-response design. In the adaptive alpha allocation approach (4A)
by Li and Mehrotra (Li and Mehrotra, 2008), the hypotheses are grouped into two
families on the basis of previous trial power and allows the significance level for the
second underpowered family to be set adaptively based on the largest observed p-value
in the adequately powered first family.
Dunnett Test
The Dunnett procedure is based on the joint distribution and thus accounts for the
correlation among the test statistics, and it was originally developed for the multiplicity
problems in multiple dose-control comparisons. Consider a multiple arm clinical trial
comparing K doses or treatments to a control group, in which xkj is the response of
the jth individual in the kth treatment group, k = 0, . . . , K (where k = 0 denotes the
control group). The t statistic for testing Hk is: tk =
x¯k−x¯0
s
√
2/n
, with s as the pooled
sample standard deviation. The test statistic for testing global null is:
T = max
k
tk. (1.1)
The multivariate t-distribution of T in Eq (1.1) is one-sided Dunnett distribution with
degree of freedom of ν = (K + 1)(n− 1). The Dunnett critical value, µα = F−1(1−α),
is evaluated under the global null hypothesis, where F (x) is the CDF of Dunnett
distribution. The individual hypothesis Hk is rejected if tk ≥ µα, k = 1, . . . , K.
Adaptive Alpha Allocation Approach
Li and Mehrotra (Li and Mehrotra, 2008) proposed an adaptive alpha allocation
7approach (4A), which is a data-driven approach. 4A controls the FWER at level
α and can notably increase the probability of achieving a positive trial compared
with fixed prospective alpha allocation scheme. The research work discussed the
testing procedures for the independent and correlated endpoints. For the independent
endpoints, endpoint A is tested at the pre-specified level α1 = α− , and the endpoint
B is tested at the adaptive level:
α2(pA, α1, α) =
{
α, if pA ≤ α1;
min( αt
p2A
, α1), if pA > α1,
where
αt =
{
α1(1−
√
2α1−α−α21
α1
)2, if α1 + α
2
1 − α31 ≤ α;
α1
α−α1
1−α1 , if α1 + α
2
1 − α31 > α,
The extension to three or more independent primary endpoints is also discussed,
where the tests for the type A endpoints are tested at level α1 using any multiplicity
adjustment procedure, such as Hommel or Hochberg methods. The p-values for the
type B primary endpoints are then assessed at an adaptive overall level based on the
observed largest p-value for type A endpoints using multiplicity adjustment procedure.
The adaptation method for the correlated primary endpoints is also available in (Li
and Mehrotra, 2008).
Recently, more advanced testing approaches have been introduced. The gatekeeping
approach based on the closure principle (Dmitrienko et al., 2006a) is an appropriate
method in the situation when one family of hypotheses treated as a gatekeeper and
8the other families are tested only if one or more gatekeeper hypotheses have been
rejected. However, the gatekeeping procedure is difficult to communicate with the
non-statisticians and requires large set of tests as the number of individual hypotheses
increases. An iterative graphical approach (Bretz et al., 2009) deals with those
weakness, and constructs the Bonferroni-type tests with a simple updating algorithm
that fully describes a sequentially rejective test procedure. Bretz (Bretz et al., 2011)
described these ideas with more details and further extensions, including weighted
Bonferroni, Simes and parametric tests.
Graphical Approach
The iterative graphical approach is used to construct and perform Bonferroni-type
tests, which is represented by directed and weighted graphs with visualized expression.
Using a graphical approach, the hypotheses are represented by a set of vertices with
local significance levels. The weight associated with a directed edge between any two
vertices indicates the fraction of the significance level at the initial vertex that is added
to the significance level at the terminal vertex, if the hypothesis at the initial vertex
is rejected. Let α1, . . . , αK be the initial allocation of the overall significance level
for each hypothesis such as
∑K
k=1 αk ≤ α. Figure (1·1) shows the graphical approach
for two and three hypotheses. For two hypotheses testing in Figure (1·1.A), if H1 is
rejected at α1, the initially allocated significance level for H1 is passed to H2, then
H2 is tested at α. Vice versa, if H2 is rejected at α2, then H1 is tested at level α.
Similarly, Figure (1·1.B) shows the illustration for the three hypotheses with the equal
initial significance level allocation and the equal edges of fraction recycling.
9Figure 1·1: Graphical illustration of the weighted Bonferroni-Holm
procedure with two and three hypotheses (Bretz et al., 2009).
1.2 Group Sequential Design
Group sequential designs (GSD) are clinical trials which allows interim looks with the
possibility of early terminations due to efficacy, harm or futility, in such a way as to
maintain a prescribed significance level and power against alternatives. Therefore,
GSD can also help in reducing the overall costs and timelines for the development of
a new drug. Repeated looks of data may inflate the Type I error rate due to multiple
testings of interim analyses, and the proper treatments to the error inflation haven been
discussed widespreadly. Simple group sequential approaches for a pre-specified number
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of equally spaced interim analyses were developed (Pocock, 1977; O’Brien and Fleming,
1979) by adjusting the critical values to control the type I error. Wang and Tsiatis
(Wang and Tsiatis, 1987) generalized Pocock and O’Brien and Fleming methods to
a class of boundaries with a shape parameter. However, those approaches require
the fixed maximum number of analyses with equally spaced interims and therefore
lack in flexibility. Lan and DeMets (Lan and DeMets, 1983) proposed an alternative
method of using α-spending functions to construct discrete sequential boundaries, in
which the boundary at each decision time is determined by the information time of the
interim analysis. The Lan and DeMets approach has been extended to one-parameter
family of α-spending functions in order to construct customized designs (Kim and
DeMets, 1987; Hwang et al., 1990), and been generalized to futility test of interim
analyses using type II error spending function (Pampallona et al., 2001). The spending
function approach has become popular because of its flexibility in allowing unequally
spaced interim analyses and some room for changing the interim analyses on the
condition of no knowledge of treatment effects. Most literature about GSD focuses on
a single endpoint, however, GSD with multiple endpoints has also received considerable
attention.
Pocock Boundary
Pocock (Pocock, 1977) proposed to perform a test at a constant nominal level at
each interim analysis. Suppose a group sequential design with M planned repeated
looks, and Zm is the test statistic at m
th stage. Let Cp(M,α) be the Pocock stopping
boundary for the test level of α. Then the Pocock’s test is as follows:
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• In the mth stage (m = 1, . . . ,M − 1), if |Zm|> CP (M,α), then stop the trial and
reject H0; otherwise continue to the (m+ 1)
th stage.
• In the last stage, if |ZM |> CP (M,α), then stop the trial and reject H0; otherwise
stop and accept H0.
O’Brien and Fleming Boundary
Contrast to Pocock’s test, O’Brien and Fleming (O’Brien and Fleming, 1979) suggested
a test by increasing the nominal significance level for each stage analysis, which makes
it difficult to reject the null hypothesis at the early stage of the trial. The OBF test is
as follows:
• In the mth stage (m = 1, . . . ,M − 1), if |Zm|> COBF (M,α)
√
M/m, then stop the
trial and reject H0; otherwise continue to the (m+ 1)
th stage.
• In the last stage, if |ZM |> COBF (M,α), then stop the trial and reject H0; otherwise
stop and accept H0.
Error Spending Function Approach
The error spending function was proposed to offer more flexibility of study design. Let
τ denote the information time during the course of a clinical trial, where τ = n/N , n
is the accumulative sample size at the time of interim analysis and N is the target
sample size. The alpha spending function, α(τ), is a monotonically increasing function.
At the beginning of trial (τ = 0), α(τ) = 0; and at the end of trial (τ = 1), α(1) = α,
which is the overall significance test level. Once an interim analysis is performed, part
of the overall alpha is spent for testing. For the interim analysis at the information
time of τ , α(τ) determines the probability of any of the interim analyses before τ
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leading to rejection of the null hypothesis when the null hypothesis is true. The
stopping boundary requires numerically integrating the distribution function.
1.3 Drop-the-Loser Design
A drop-the-loser adaptive design (DLD) is useful in phase II and sometime phase III
clinical development especially when there are uncertainties regarding the dose levels.
Usually, in the first stage of a two-stage DLD, the candidates for the best treatment
based on the efficacy are selected. At the second stage, additional observations are
collected in those candidate arms and control arm to decide whether the candidate is
actually better than the control. DLDs allow for multiple treatment arms with the
opportunity to more fully characterize the dose-response during the initial phase of the
trial. An interim analysis plan specifies the criteria for dropping doses/treatments that
fail to show clinically meaningful efficacy over placebo. The doses/treatments satisfying
interim efficacy criteria are continued to completion. This adaptive pruning permits
the randomization of remaining participants to the conditions which demonstrate the
most encouraging performance.
Pick-the-Winner Design
The straightforward example of DLD is a two-stage pick-the-winner which only allows
one winner arm selected in the interim stage carried to the final stage (Chang, 2014).
Suppose a trial starts with K treatment arms and one control arm. The sample
size for each group is N, and the interim analysis will perform at the information
time τ = N1
N
. The treatment arm with the maximum efficacy in the interim analysis
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and the control arm will be carried and additional N2 = N −N1 individuals in each
arm will be recruited. Let x¯k be the mean of the first stage data for the k
th arm
(k = 0, 1, . . . , K), and y¯k be the mean of the incremental second stage data from
N(µk, σ
2), where k = 0, S, and arm S is the treatment arm selected in the interim.
Let tk =
x¯k
σ
√
N1 and τk =
y¯k
σ
√
N2 be the stagewise test statistics, respectively. Then
the maximum statistic at the end of the first stage is T1 = max(t1, . . . , tK), with the
pdf as fT1(t) = K[Φ(t)]
K−1φ(t). Let δk = 1 when k = S, otherwise δk = 0. Then the
cdf of the statistic T2 for the winner arm in the final stage is:
FT2(t) =
K∑
k=1
P (δk = 1 ∩ T1
√
τ + τi
√
1− τ < t). (1.2)
The final test statistic is defined as: T ∗2 = (T2 − t0)/
√
2, with the pdf as:
FT ∗2 (z) =
∫ ∞
−∞
FT2(t)φ(
√
2z − t)dt. (1.3)
The stopping boundary can be derived from Eq. (1.3) by solving FT ∗2 (z) = 1−α. This
design only allows to reject H0 at the final analysis. Additionally, a lot of different
DLD designs are existing which have diversified dropping arms manners as long as
the criterion is defined in the beginning of the trial.
1.4 Dissertation Outline
In this dissertation, we study the multiple testing problems in the classical clinical
trials and adaptive designs, and develop the novel testing procedures to solve the
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multiple testing problems in the different study design. The complete methods and
the corresponding simulation studies are presented in each chapter.
In Chapter 2, we develop a single-step progressive parametric multiple (SPPM)
testing procedure, which considers the joint distribution of the test statistics. The
procedure constructs the testing using the products of all the combinations of local
individual p-values and the critical values are determined by numerical integrations
progressively using the closure principle. The performance of the SPPM has been
compared through extensive simulations to several other existing multiple testing
procedures, which demonstrate the advantage of using the SPPM procedure, in terms
of power, for the certain situations of multiple testing. The method can also take the
clinical importance and/or statistical power into consideration when distributing the
error rate among the individual hypotheses. An application of SPPM to a Phase III
dose-finding trial is also presented.
In Chapter 3, an intuitive approach is proposed, which utilizes the multivariate
normal distribution to deal with multiplicity issues arising from multiple endpoints
and from multiple looks in group sequential design. The approach is a closed testing
procedure, and therefore it controls the familywise error rate in a strong sense.
The procedure could also have various applications in other designed trials, such
as biomarker design and multiple-arm design. In addition, we discuss the alpha-
reallocation to improve the conjunctive power of rejecting all endpoints with the FWER
controlled for special requirements in the clinical trial designs. Through extensive
simulations, the proposed method is demonstrated to gain the power compared to the
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Bonferroni correction for multiple primary endpoints in group sequential designs when
the correlation among endpoints exists and has some power advantages compared to
the Tang and Geller method when the effect sizes differ.
In Chapter 4, we propose the flexible drop-the-loser designs based on the traditional
Dunnett test and the pick-the-winner design in the gatekeeping testing manner, both
of which allow more flexibility of treatment selections without pre-specified mechanism
and still retain acceptable power. The simulation study is conducted for different
combinations of efficacy and safety response curves using two flexible DLD designs,
and the power performance shows different patterns for two methods according to
the response curves. In addition, the drop-the-loser design in the gatekeeping testing
manner is explored with the adjustable sample size in the interim if the winner arm
based on the efficacy data is discontinued due to the safety issue. The utility function,
as a measurement of balance between efficacy and toxicity, is also included as the
criterion of treatment selection for the two methods.
The three topics in the chapters are introduced to solve the multiple testing
problems in different study design: SPPM testing procedure is proposed to improve
the power for union-intersection testing problem, which can be applied in the multiple
primary endpoints design, multiple arm design in the classical clinical trial; GSMulti
procedure is designed to improve the power of multiple primary endpoints in GSD,
where the multiplicity problem comes from endpoints and repeated looks; the two
extension methods of drop-the-loser design (DLD) is developed to improve the power
in the multiple arm adaptive designs, and the multiplicity comes from pairwise
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comparisons among arms. These three projects show the importance of correlation
in the multiple testing procedures. The critical values of SPPM and GSMulti are
derived based on the correlation and both two methods demonstrate the advantage
of utilizing the correlation in terms of boosting power. For DLD designs, the critical
values are based on Dunnett test, where the joint distribution of test statistics are
considered when deriving the critical values as well. In summary, my dissertation is
dealing with the multiplicity issues in general, and the information about correlation
could be used when we design a trial.
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Chapter 2
Single-Step Progressive Parametric
Multiple Testing Procedure for Correlated
Normal Test Statistics
2.1 Introduction
In general, multiplicity is from the simultaneous evaluation of different aspects of
the efficacy or safety profile of a treatment (Dmitrienko et al., 2013).The statistical
methods for multiple testing have gradually gained importance with the increasing
number of complex clinical trial designs.
Two types of global multiple hypotheses testing can be performed (Dmitrienko
et al., 2009): union-intersection testing (UIT) and intersection-union testing (IUT).
We focus on the UIT framework in the dissertation. The null hypothesis of UIT is
an intersection hypotheses, and the global null hypothesis is rejected if at least one
of its individual null hypotheses is rejected. In UIT framework, the familywise error
rate (FWER) - the probability of falsely rejecting at least one null hypothesis - is
required to be controlled in the strong sense at level α, which means FWER≤ α in
18
spite of which other hypotheses are true. A modification of testing procedure needs to
be done to control the error strongly. A number of methods have been developed for
controlling the FWER within the acceptance limit, including single-step and stepwise
procedures. In single-step approaches, such as the simple Bonferroni method and the
Sidak method (Sˇida´k, 1967), the rejection decision of a hypothesis does not depend on
the decision of any other hypotheses. Single-step approaches can be improved in terms
of power through stepwise approaches, while also controlling for the desired error rate.
With stepwise approaches, some hypotheses may be retained or rejected by implication
of decisions about other hypotheses. Stepwise procedures include the Holm stepdown
method (Holm, 1979), the Hochberg step-up procedure (Hochberg, 1988) and the
Hommel step-up procedure (Hommel, 1988) and so on. The fixed-sequence testing
approach (Maurer et al., 1995), (Westfall et al., 2011) is also one category of stepwise
procedure that assumes the order in which the hypotheses are tested is pre-specified
before the data collection. A compromise between the Holm and the fixed-sequence
procedures can be obtained by the fallback procedure introduced by Wiens (Wiens,
2003) and was further studied (Wiens and Dmitrienko, 2005), (Dmitrienko et al.,
2006b). When the adjusted p-value for each hypothesis is found based on the collected
data, the stepwise procedure is simplified to the situation that the adjusted p-values
are compared against significance α level in any testing order.
However, it is also possible to improve the power by utilizing a parametric procedure
with the known or assumed joint distribution of the test statistics. The most well-
known parametric procedure was developed by Dunnett (Dunnett, 1955) for the
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dose-response design. The stepwise version of Dunnett procedure (Marcus et al.,
1976), (Dunnett and Tamhane, 1992) can boost power compared to the single-step
one. Huque and Alosh (Huque and Alosh, 2008) proposed a flexible fixed-sequence
testing procedure, which takes into account correlations among endpoints for higher
flexibility. In the adaptive alpha allocation approach (4A) by Li and Mehrotra (Li and
Mehrotra, 2008), the hypotheses are grouped into two families on the basis of previous
trial power and allows the significance level for the second underpowered family to be
set adaptively based on the largest observed p-value in the adequately powered first
family. Li et al. (Li et al., 2013) generalized 4A and used well-defined functions of the
joint distribution of multiple endpoints to calculate the alpha allocation for the second
family. Some advanced testing approaches also have been introduced. An iterative
graphical approach (Bretz et al., 2009) constructs the Bonferroni-type tests with an
updating algorithm that fully describes a sequentially rejective test procedure, which
is easier to communicate to the non-statisticians. Bretz (Bretz et al., 2011) described
these ideas with further extensions, including the parametric tests.
Littell and Folks (Littell and Folks, 1971), (Littell and Folks, 1973) showed that the
Fisher’s combination test (Fisher, 1932) is asymptotically optimal among essentially all
methods of combining independent tests. The extensions of the Fisher’s combination
test allowing the dependent tests are available for both completely specified covariance
matrix (Brown, 1975) and partially defined covariance matrix with a known scalar
quantity (Kost and McDermott, 2002). However, those product combination tests
are global tests and control the FWER only when all null hypotheses are true, thus,
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provide weak control of the FWER. There are a number of applications of Fisher’s
method in the adaptive designs as well (Bauer and Kohne, 1994), (Wassmer, 1999),
(Hommel et al., 2005), (Go¨tte et al., 2009), (Schmidt et al., 2014). Based on Fisher’s
method, Bauer and Ko¨hne (Bauer and Kohne, 1994) designed a two-stage adaptive
design controlling the FWER in the strong sense, which was also considered for K > 2
stages design (Wassmer, 1999). Hommel et al. (Hommel et al., 2005) proposed the
modified Simes test for a two-stage adaptive design with correlated test statistics, and
Go¨tte et al. (Go¨tte et al., 2009) extended MST and generalized (Bauer and Kohne,
1994) for correlated test statistics. In this chapter, we propose a straightforward but
powerful single-step progressive parametric multiple (SPPM) testing procedure using
the product combination as well and taking the correlation into account. The procedure
constructs the testing using the products of all the combinations of local individual
p-values as well, and the critical values are determined by numerical integrations
progressively using the closure principle, therefore, the procedure can strongly control
the FWER. It also allows the possibility of different allocation of significance level
α according to the effect sizes or the clinical importance. The simulation studies
demonstrate our procedure improves power substantially when the correlation is
moderate and the difference in the effect sizes is small.
This chapter evolves as follows. We begin with a description of the proposed
single-step progressive parametric multiple testing procedure in two-hypothesis testing
and the critical values are derived mathematically using numerical integration, followed
by the extension to three-hypothesis. The extensive simulation studies demonstrate
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that in most situations the proposed procedure is more powerful than the current
broadly used methods. The “Discussion” section concludes the topic with a short
summary and discussion of future potential work.
2.2 Single-step Progressive Parametric Multiple Testing Pro-
cedure
2.2.1 Two-Hypothesis Testing Procedure
First, we discuss the situation of two one-sided test hypotheses in the UIT framework:
H0 : µ1 ≤ 0 ∩ µ2 ≤ 0(H1 ∩H2) v.s Ha : µ1 > 0 ∪ µ2 > 0(H¯1 ∪ H¯2), (2.1)
where Hk and H¯k are the null and alternative hypotheses for the k
th test (k = 1, 2),
respectively. The single-step progressive parametric multiple (SPPM) testing procedure
is performed as follows:
• If p1p2 ≤ α1 and p1 ≤ α0, reject H1;
• If p1p2 ≤ α2 and p2 ≤ α0, reject H2,
where pk is the univariate local p-value forHk, and α
′
ks are the critical values. According
to the closure principle, a hypothesis is rejected if all intersection hypotheses containing
this hypothesis are rejected, and testing each intersection hypothesis using a local
α-level can strongly control the FWER. For example, to reject H1 at α-level, we need
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to control the error rate at α under H1 and H0. Therefore, we have:
Pr1 = sup
µ1∈H1
Pr(Reject H1|H1) = sup Pr(p1p2 ≤ α1 ∩ p1 ≤ α0|H1) ≤ α;
Pr2 = sup
µ2∈H2
Pr(Reject H2|H2) = sup Pr(p1p2 ≤ α2 ∩ p2 ≤ α0|H2) ≤ α;
Pr0 = sup
µ′ks∈H0
Pr(Reject at least one Hk|H0)
= Pr(p1p2 ≤ α1 ∩ p1 ≤ α0|H0) + Pr(p1p2 ≤ α2 ∩ p2 ≤ α0|H0)
− Pr(p1p2 ≤ min(α1, α2) ∩ p1 ≤ α0 ∩ p2 ≤ α0|H0) ≤ α.
It is easy to obtain that α0 ≤ α from Pr1 or Pr2, and α0 = α is used to exhaust
α and improve the power. Moreover, we also see the idea behind this procedure is
to borrow strength among the marginal p-values, that is, there is no need to make
an α adjustment to reject H1 as long as p1 ≤ α and p2 is small. Afterwards, the
critical values α1 and α2 are determined by controlling Pr0 at α. Our SPPM testing
procedure has both coherence and consonance properties. It is coherent due to the
closure principle, and is consonant because rejecting an intersection hypothesis Hi
will lead to the rejection of at least one Hk implied by Hi. In addition, the rejection
decision of Hk in SPPM testing procedure depends on the observed data from other
hypotheses, however, it is a single-step testing procedure because the rejection or
non-rejection of a single hypothesis Hk does not depend on the decision on any other
hypothesis. Therefore, the proposed procedure can test hypotheses simultaneously
or in any order. It can be shown by the extensive simulations that the worst case
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under the global null is when all µ′ks equal to 0 (see Appendix A for details). Then
Pr0 is simplified as Pr(Reject at least one Hk) ≤ α under H∗0 : µ1 = µ2 = 0, and this
simpler and more convenient condition is used for derivations of critical values.
Here, we assume that the test statistic for the kth hypothesis is Zk ∼ N(µk, 1)
with univarite p-value pk, then pk follows Uniform(0,1) under Hk. The correlation
between Z1 and Z2 is denoted by ρ. By the property of the multivariate normal
distribution (Eaton, 1983), the conditional distribution of Z2, given Z1 = z1, is
N(µ2 + ρ(z1 − µ1), 1− ρ2). Then, the conditional cumulative density function (CDF)
for p1p2 given p1, under H
∗
0 , is:
Pr
p1p2|p1
(p1p2 ≤ α1|p1) = Pr(p2 ≤ α1
p1
|p1)
=
 1,
α1
p1
≥ 1;
Pr(Z2 ≥ Φ−1(1− α11−Φ(z1))|Z1 = z1) = 1− g(p1),
α1
p1
≤ 1.
where we define g(x) := Φ((Φ−1(1− α1
x
)− ρΦ−1(1− x))/√1− ρ2). The type I error
rate for H1 under H
∗
0 is:
Pr(p1p2 ≤ α1 ∩ p1 ≤ α|H∗0 ) =
{
Pr(p1 ≤ α|H∗0 ), α1 ≥ α;∫ α
0
Prp1p2|p1(p1p2 ≤ α1|p1)f(p1)dp1, α1 < α.
=
{
α, α1 ≥ α;
α− ∫ α
α1
g(p1)dp1, α1 < α.
(2.2)
The type I error rate for H2 under H
∗
0 : Pr(p1p2 ≤ α2 ∩ p2 ≤ α|H∗0 ) can be derived in
a similar manner. Next, the probability of rejecting two hypotheses simultaneously
should be obtained in the two situations defined by the value of min(α1, α2). When
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α2 ≤ min(α1, α2), we have:
Pr(p1p2 ≤ min(α1, α2) ∩ p1 ≤ α ∩ p2 ≤ α|H∗0 ) = Pr(p1 ≤ α ∩ p2 ≤ α|H∗0 )
= Pr(Z1 ≥ Φ−1(1− α) ∩ Z2 ≥ Φ−1(1− α)|H∗0 ) =: FZ ,
When α2 > min(α1, α2) = α1, the probability becomes:
Pr(p1p2 ≤ α1 ∩ p1 ≤ α ∩ p2 ≤ α|H∗0 )
=
∫ α1
α
0
Pr(p2 ≤ α|p1)dp1 +
∫ α
α1
α
Pr(p2 ≤ α1
p1
|p1)dp1
=α− (
∫ α1
α
0
h(p1)dp1 +
∫ α
α1
α
g(p1)dp1),
where we define h(x) := Φ((Φ−1(1−α)−ρΦ−1(1−x))/√1− ρ2).When min(α1, α2) =
α2, the probability of rejecting two hypotheses simultaneously can be written in the
same way with α1 replaced by α2. To summarize,
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P1 = sup
µ1∈H1
Pr(Reject H1|H1) ≤ α;
P2 = sup
µ2∈H2
Pr(Reject H2|H2) ≤ α;
P0 = sup
µk∈H0
Pr(Reject at least one Hk|H0) =
2α− FZ , α ≤ α1 ≤ α2;
2α− ∫ α
α1
g(p1)dp1 − FZ , α2 ≤ α1 < α ≤ α2;
2α− ∫ α
α1
g(p1)dp1 −
∫ α
α2
g(p2)dp2 − FZ , α2 ≤ α1 ≤ α2 < α;
α− ∫ α
α1
g(p1)dp1 +
∫ α1
α
0
h(p1)dp1 +
∫ α
α1
α
g(p1)dp1, α1 < α
2 < α ≤ α2;
α− ∫ α
α1
g(p1)dp1 −
∫ α
α2
g(p2)dp2 +
∫ α1
α
0
h(p1)dp1+
∫ α
α1
α
g(p1)dp1,
α1 < α
2 and α2 < α.
(2.3)
The critical values α1 and α2 are determined by satisfying P0 ≤ α in Eq. (2.3). How-
ever, the condition α ≤ αk is not viable because there is no solution between 0 and
1 and p1p2 ≤ αk in the testing procedure actually no longer has any effect for this
condition. In the simple case of α1 = α2, we have:
2α− 2
∫ α
α1
g(p1)dp1 − FZ(Φ−1(1− α),Φ−1(1− α)) ≤ α, α2 ≤ α1 = α2 < α. (2.4)
The critical values α1 = α2 for a one-sided test under different correlations given
various significance level α are shown in Table 2.1. 100, 000 simulations also succeeded
to verify that the critical values derived mathematically strongly control the FWER
as shown in Appendix E. From Table 2.1, the critical values are decreasing with the
increase in correlation, which indicates the most conservative condition for SPPM
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given the multivariate normal distribution of test statistics with known covariance
matrix is when the two test statistics are perfectly correlated (ρ = 1). If the correlation
is not considered and the critical values with ρ = 0 is used, the FWER will be inflated
especially when the true correlation is strong. For practical use, the critical value α1
for the test with a correlation that is not listed in Table 2.1 can be obtained using a
linear interpolation; or, a conservative value can be used. For example, if α = 0.025
and correlation ρ = 0.08, the critical value of 0.004085 for ρ = 0.1 could be chosen.
We also provided the R functions in Appendix B to calculate the critical values for all
the situations of α1 and α2.
Table 2.1: Critical values of one-sided test for two-hypothesis test with
different correlations when α1 = α2.
ρ α = 0.01 α = 0.025 α = 0.05 ρ α = 0.01 α = 0.025 α = 0.05
0 0.00190 0.00486 0.01010 0.45 0.00058 0.00203 0.00546
0.05 0.00171 0.00446 0.00947 0.5 0.00049 0.00182 0.00508
0.1 0.00152 0.00409 0.00888 0.55 0.00042 0.00163 0.00472
0.15 0.00135 0.00373 0.00831 0.6 0.00035 0.00146 0.00439
0.2 0.00119 0.00340 0.00776 0.65 0.00030 0.00131 0.00408
0.25 0.00104 0.00308 0.00725 0.7 0.00025 0.00117 0.00380
0.3 0.00090 0.00279 0.00676 0.75 0.00022 0.00105 0.00353
0.35 0.00078 0.00251 0.00630 0.8 0.00018 0.00094 0.00329
0.4 0.00067 0.00226 0.00587 0.85 0.00016 0.00085 0.00306
2.2.2 Three-Hypothesis Testing Procedure
The null and alternative hypotheses for three hypotheses are written as:
H0 : H1 ∩H2 ∩H3 vs. Ha : H¯1 ∪ H¯2 ∪ H¯3, (2.5)
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where Hk and H¯k are the null and alternative hypothesis for the k
th test (k = 1, 2, 3),
respectively. Analogous to the two-hypothesis testing procedure in Section 2.2.1, the
SPPM procedure is conducted as:
• If p1p2p3 ≤ α4, pipj ≤ αi and pipj′ ≤ αi and pi ≤ α0, reject Hi; otherwise, accept
Hi;
where i, j, j′ = 1, 2, 3, i 6= j 6= j′, and the critical values are α1, . . . , α4. According to
the closure principle, each hypothesis below is tested at α-level:
Pri = sup
µi∈Hi
Pr(Reject Hi|Hi) ≤ α,
Prij = sup
µi,µj∈Hi∩Hj
Pr(Reject either Hi or Hj|Hi ∩Hj) ≤ α,
Pr0 = sup
µ′is∈H0
Pr(Reject at least one Hi|H0) ≤ α,
(2.6)
where Pri and Prij(i, j = 1, 2, 3, i 6= j) have the same formulations as the FWERs un-
der single hypothesis testing and two-hypothesis testing, respectively (see Appendix C
for details). We again have α0 = α to use up α and maximize the power. The equal
pairwise correlations among three test statistics are assumed for now and α1 = α2 = α3,
the critical values in Table 2.1 can be used for α′ks (k = 1, 2, 3) here. Given α
′
ks,
α4 is determined progressively by solving Pr0 = α. However, when the pairwise
correlations differ, the assumption of α1 = α2 = α3 can no longer be valid and the
critical values should be derived according to Eq. (2.6) one step by one. The critical
values α4 for the three-hypothesis testing under various α and the equal pairwise
correlation ρ are listed in Table 2.2. The first line in each cell is the critical values
α1 = α2 = α3 and the second line is the critical values α4. From Table 2.2, α4 is 1
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in some situations, which indicates no need for the criterion of p1p2p3 ≤ α4 and the
FWER can be controlled implicitly by the other criteria. The R functions for the
critical values in three-hypothesis testing assuming the equal pairwise correlation is
also provided in Appendix D.
Table 2.2: Critical values of one-sided test for three-hypothesis test
with different correlations (α1 = α2 = α3).
ρ α = 0.01 α = 0.025 α = 0.05 ρ α = 0.01 α = 0.025 α = 0.05
0 0.00190 0.00486 0.01010 0.45 0.00058 0.00203 0.005460.00111 0.00268 0.00516 1 0.00079 0.00165
0.05 0.00171 0.00446 0.00947 0.5 0.00049 0.00182 0.005080.00098 0.00235 0.00458 1 0.00108 0.00145
0.1 0.00152 0.00409 0.00888 0.55 0.00042 0.00163 0.004720.00086 0.00205 0.00406 1 1 0.00129
0.15 0.00135 0.00373 0.00831 0.6 0.00035 0.00146 0.004390.00074 0.00177 0.00358 1 1 0.00115
0.2 0.00119 0.00340 0.00776 0.65 0.00030 0.00131 0.004080.00065 0.00152 0.00315 1 1 0.00105
0.25 0.00104 0.00308 0.00725 0.7 0.00025 0.00117 0.003800.00058 0.00131 0.00277 1 1 0.00100
0.3 0.00090 0.00279 0.00676 0.75 0.00022 0.00105 0.003530.00060 0.00112 0.00243 1 1 1
0.35 0.00078 0.00251 0.00630 0.8 0.00018 0.00094 0.003291 0.00097 0.00214 1 1 1
0.4 0.00067 0.00226 0.00587 0.85 0.00016 0.00085 0.003061 0.00086 0.00188 1 1 1
For example, when α = 0.01 and ρ = 0, the critical values α1 = α2 = α3 = 0.0019, and
α4 = 0.00111.
2.3 Simulation Study
The emerging approaches dealing with the multiplicity problems have not shown
substantial power improvement for a long time. In this section, the proposed SPPM
testing procedure is compared to several popular approaches through extensive simula-
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tions and is established to be more powerful when having similar effect sizes and small
or moderate correlation. The power of the situation with the differential effect sizes can
also be improved by modifying the critical values for two- and three-hypothesis testing
procedures. We also investigated the FWER with estimated covariance matrix when
the correlation and variance are unknown and showed the SPPM testing procedure
can control the FWER strongly.
2.3.1 Power Comparisons of Two-Hypothesis Testing
We first study the performance of SPPM in terms of power compared to other methods
in the two-hypothesis framework. The nonparametric testing procedures, including
single-step and stepwise procedures, and the parametric testing procedure are evaluated
together. The Bonferroni test is compared as a benchmark for the evaluation of power
improvement. We also includes the Hochberg and Hommel procedures, the fallback
procedure, the step-up Dunnett procedure and 4A method for comparison as well.
The FWERs of the existing methods are shown to be controlled well under the
situations of the positively dependent test statistics, although some testing procedures
could be conservative with strong correlations; the proposed SPPM procedure is
derived under strong control of the FWER and was also verified by simulations to
control the FWER (see Appendix E). Therefore, the power can be investigated directly
on the same significance level at α = 0.025. The two correlated endpoints with sample
size N as 90 were simulated and one-sample test was conducted with known covariance
matrix. Based on 100,000 simulations, Table 2.3 shows the powers for four values of
30
known ρ: 0, 0.25, 0.5, 0.75, and three sets of effect sizes µ1 and µ2. Two different
types of power are shown here: the power of rejecting H1 and H2 at the same time,
denoted as Power1 and the power of rejecting either H1 or H2, denoted as Power. The
main interest is the power of rejecting either of hypotheses, but the power of rejecting
both is also presented for reference since this probability is sometimes useful in the
clinical trials, for example, when trying to label the drug on two or more endpoints
if the trial is claimed efficacy. For the Bonferroni and fallback procedures, the equal
weights w1 = w2 = 0.5 are used. The hypothesis with µ2 = 0.3 is tested first in
the fallback procedure to achieve the higher Power1. For the 4A method, p-value
for the adequately powered hypothesis (µ2 = 0.3) is α1 = 0.02 and p-value for the
underpowered hypothesis is assessed at an adaptive overall level α2 based on the
observed p-value considering the correlation. For the SPPM procedure, we assess three
different sets of critical values: SPPMe for α1 = α2; SPPM
u
1 for 3α1 = α2; SPPM
u
2 for
10α1 = α2.
Table 2.3 shows the power under various settings, and the highest power among
different testing procedures are in bold. In the two-hypothesis testing framework,
the Hochberg and Hommel procedures have the same power due to their testing
algorithms. Overall, when the effect sizes are in the same direction, the SPPM
procedure outperforms other methods in terms of Power of rejecting at least one
hypothesis (Power) and has the comparable power of rejecting both hypotheses
(Power1). The SPPM with equal critical values (SPPMe) has higher power than other
existing methods when the correlation and/or the discrepancy in the effect sizes are
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small; otherwise, the power improvement of SPPMe vanishes. The performance of
the step-up Dunnett procedure is not affected too much by the inconsistency in the
effect sizes and has a higher power than the nonparametric procedures when there is a
strong correlation between two endpoints as expected. The 4A procedure has obvious
advantage when the two effect sizes are different since it aims to accommodate the
underpowered hypotheses/endpoints but the prior knowledge is necessary to achieve
high power. Those investigated existing approaches are more powerful when one of
hypothesis has negative mean, while SPPM procedure provides low power. Although,
the SPPM testing procedure does not statistically improve power uniformly, this is
actually the desired feature of the proposed procedure from the perspective of clinical
trials because, for example, (1) for two endpoints, if one endpoint shows positive effect
and the other shows negative effect, the overall benefit of the drug might diminish,
the probability of approving such a drug should be small; similarly, (2) in the case
of two doses, if one dose has positive effect and the other dose has a negative effect,
we should be very caution in approving the drug since patient might not take exact
amount of dose as indicated. In this sense, SPPM emphasizes the consistency of the
results or the totality of evidence while controlling the FWER as well.
One reason that the SPPMe has lower power in some of the situations is that
such a specific defined procedure highlights the consistency of the evidence against
both hypotheses, while the inconsistency clearly exists in the case with different effect
sizes. Fortunately, Eq. (2.3) allows us to allocate α1 and α2 differently as for SPPM
u
1
and SPPMu2 in order to account for the differential evidence. In general, SPPM
u
1 and
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SPPMu2 have similar powers when the effect sizes are similar from Table 2.3. The
powers of three SPPM procedures are distinguished from each other when a large
difference in the effect sizes exists, and the phenomenon of differential powers is more
obvious with the increasing correlation. SPPMe performs poorly for the small µ1, but
the procedure is improved in terms of power by using different α1 and α2.
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Table 2.3: Power comparisons for two-hypothesis testing with different correla-
tions (µ2 = 0.3, σ = 1).
Method µ1 = −0.15 µ1 = 0.15 µ1 = 0.3
Power1 Power Power1 Power Power1 Power
ρ = 0
Bonferroni 0.0001 0.729 0.151 0.784 0.531 0.927
Fallback (H2, H1) 0.0003 0.729 0.217 0.784 0.592 0.927
Hommel/Hochberg 0.0003 0.729 0.242 0.792 0.661 0.934
Step-up Dunnett 0.0003 0.729 0.242 0.792 0.661 0.934
4A¶ 0.0003 0.786 0.234 0.792 0.639 0.855
SPPMe 0.0003 0.631 0.242 0.844 0.661 0.963
SPPMu1 0.0003 0.695 0.242 0.855 0.661 0.961
SPPMu2 0.0003 0.746 0.242 0.854 0.661 0.953
ρ = 0.25
Bonferroni 0.0001 0.729 0.173 0.762 0.56 0.898
Fallback (H2, H1) 0.0004 0.729 0.244 0.762 0.617 0.898
Hommel/Hochberg 0.0004 0.729 0.264 0.769 0.681 0.906
Step-up Dunnett 0.0004 0.729 0.264 0.769 0.681 0.906
4A¶ 0.0004 0.786 0.258 0.787 0.66 0.814
SPPMe 0.0004 0.569 0.264 0.795 0.681 0.938
SPPMu1 0.0004 0.634 0.264 0.815 0.681 0.935
SPPMu2 0.0004 0.695 0.264 0.825 0.681 0.923
ρ = 0.5
Bonferroni 0.0002 0.729 0.191 0.744 0.593 0.866
Fallback (H2, H1) 0.0004 0.729 0.270 0.744 0.645 0.866
Hommel/Hochberg 0.0004 0.729 0.282 0.749 0.706 0.875
Step-up Dunnett 0.0004 0.734 0.282 0.754 0.706 0.877
4A¶ 0.0004 0.787 0.279 0.787 0.687 0.793
SPPMe 0.0004 0.499 0.282 0.737 0.706 0.903
SPPMu1 0.0004 0.564 0.282 0.770 0.706 0.899
SPPMu2 0.0004 0.634 0.282 0.794 0.706 0.885
ρ = 0.75
Bonferroni 0.0002 0.730 0.204 0.732 0.635 0.824
Fallback (H2, H1) 0.0004 0.730 0.291 0.732 0.68 0.824
Hommel/Hochberg 0.0004 0.730 0.295 0.735 0.738 0.838
Step-up Dunnett 0.0004 0.746 0.295 0.751 0.738 0.847
4A¶ 0.0004 0.788 0.294 0.788 0.721 0.789
SPPMe 0.0004 0.430 0.295 0.672 0.738 0.861
SPPMu1 0.0004 0.494 0.295 0.717 0.738 0.856
SPPMu2 0.0004 0.578 0.295 0.787 0.734 0.848
Note: N = 90, one-sided α = 0.025;
The equal weights w1 = w2 = 0.5 in Bonferroni and Fallback procedures;
¶: α1 = 0.02 for the endpoint with µ2 = 0.3 in 4A procedure;
SPPMe: SPPM procedure with the equal critical values (α1 = α2);
SPPMu1 : SPPM procedure with the unequal critical values (3α1 = α2);
SPPMu2 : SPPM procedure with the unequal critical values (10α1 = α2);
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In summary, The nonparametric procedures make no assumptions about the joint
distribution of test statistics, which results in power loss when the strong correlation
exists. The step-up Dunnett improves power by taking advantage of assumptions of
the joint distribution and the 4A procedure has dominant strength when the prior
information is known with one underpowered hypotheses. The SPPM procedure
with the equal critical values improves power compared to other procedures in most
situations, although the gain in power is sensitive to the inconsistency in the effect
sizes under the alternatives. In practice, when we have little knowledge about the
magnitude of effect sizes for the small/moderate correlation, simply applying SPPMe
can provide us a powerful testing as well. In addition, if the information about the
relative effect sizes is available, the unequal critical values of the SPPM procedure
can be utilized to boost power.
2.3.2 Power Comparisons of Three-Hypothesis Testing
As concluded in Section 2.3.1, the Hochberg, Hommel, step-up Dunnett and 4A
procedures continues to be compared in the three-hypothesis testing. We also included
the parametric graphical approach as the representative of parametric procedures
for power comparisons. The equal initial allocation of the significance level (i.e.
α1 = α2 = α3 = α/3) and the same elements as 0.5 for the transition matrix are used,
which is the parametric version of the Bonferroni-Holm procedure and the same as the
step-down Dunnett test. For the 4A method, α1 = 0.02 is used again for the hypothesis
with µ3 = 0.3 and p-values for the other two hypotheses are assessed at an adaptive
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overall level α2 using Hochberg’s method. The two versions of SPPM procedure with
equal and unequal critical values are performed to examine the influence of different
α-allocations on the power. The three correlated endpoints are simulated 100,000
replicates with the same pairwise correlation and sample size N as 60. One-sample
test is again conducted with known covariance matrix. µ3 is fixed as 0.3 and we varied
µ1 and µ2 to evaluate the performance of the procedures under various correlations
(ρ = 0, 0.25, 0.5, 0.75), which is shown in Table 2.4. The largest values of power
are in bold for each scenario. The Hommel procedure is uniformly powerful than
the Hochberg procedure with a slight improvement, as also demonstrated before
(Dmitrienko et al., 2009). We observe that the SPPM procedure performs the best
among all the evaluated methods when the independent hypotheses have the effect
sizes in the same direction. When the correlation among the endpoints increases, the
advantage of the SPPM procedure with the equal critical values weakens, especially
when the effect sizes differ a lot. However, the power loss can be dealt with by using
different critical values. Since the step-up Dunnett is the data-driven method, therefore
not affected too much by the inconsistency in the effect sizes, and the 4A method
targets to improve the power for the underpowered hypotheses with prior knownledge,
SPPMu fails to beat those two methods with a large difference in the effect sizes
and/or the strong correlation, but SPPM is still comparable to some other methods
with properly adjusted critical values. Again, the SPPM testing procedure provides
lower power when some hypotheses have null effects, which is preferred sometimes in
the clinical trial setting.
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Table 2.4: Power comparisons for three-hypothesis testing with differ-
ent correlations (µ3 = 0.3, σ = 1).
Method µ1/µ2
-0.2/-0.2 -0.2/0 0.03/0.3 0.2/0.3 0.1/0.2 0.3/0.3
ρ = 0
Hochberg 0.473 0.478 0.730 0.785 0.606 0.863
Hommel 0.473 0.479 0.736 0.792 0.611 0.868
Dunnett Step-up 0.474 0.479 0.731 0.786 0.606 0.863
Graphical Approach* 0.475 0.479 0.727 0.778 0.602 0.855
4A¶ 0.609 0.609 0.655 0.664 0.620 0.697
SPPMe 0.362 0.405 0.776 0.886 0.698 0.941
SPPMu 0.537 0.549 0.754 0.842 0.702 0.903
ρ = 0.25
Hochberg 0.475 0.477 0.688 0.727 0.567 0.801
Hommel 0.475 0.477 0.694 0.733 0.572 0.807
Dunnett Step-up 0.478 0.481 0.692 0.730 0.571 0.804
Graphical Approach* 0.480 0.483 0.690 0.724 0.569 0.797
4A¶ 0.610 0.610 0.624 0.626 0.612 0.638
SPPMe 0.285 0.336 0.669 0.800 0.602 0.875
SPPMu 0.483 0.494 0.673 0.770 0.646 0.833
ρ = 0.5
Hochberg 0.473 0.474 0.645 0.668 0.53 0.737
Hommel 0.473 0.474 0.651 0.675 0.534 0.743
Dunnett Step-up 0.489 0.490 0.660 0.682 0.545 0.749
Graphical Approach* 0.492 0.492 0.659 0.678 0.544 0.743
4A¶ 0.608 0.608 0.611 0.611 0.608 0.613
SPPMe 0.187 0.250 0.553 0.708 0.511 0.797
SPPMu 0.421 0.431 0.588 0.700 0.591 0.760
ρ = 0.75
Hochberg 0.473 0.473 0.592 0.603 0.495 0.662
Hommel 0.473 0.473 0.601 0.611 0.499 0.670
Dunnett Step-up 0.516 0.516 0.633 0.641 0.537 0.694
Graphical Approach* 0.520 0.520 0.634 0.640 0.539 0.691
4A¶ 0.607 0.607 0.608 0.608 0.607 0.608
SPPMe 0.241 0.248 0.445 0.619 0.439 0.716
SPPMu 0.359 0.367 0.500 0.639 0.541 0.692
Note: N = 60, one-sided α = 0.025;
*: Equal initial allocation of α and the elements as 0.5 for the transition matrix are used;
¶: α1 = 0.02 for the endpoint with µ3 = 0.3 and the other two endpoints were assessed at an
adaptive overall level using Hochberg’s method in 4A method;
SPPMe: SPPM procedure with the equal critical values (α1 = α2 = α3);
SPPMu: SPPM procedure with the unequal critical values (10α1 = 10α2 = α3).
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2.3.3 The FWER with Unknown Covariance Matrix
The SPPM testing procedure takes into account the correlation among test statistics
to control the FWER. With the known correlation coefficient at the design stage,
the procedure could perform accurately. Correlations can also be estimated with the
sample data, however, the use of sample correlations could potentially inflate the error
rate. Additionally, it is unlikely to know the true variance sometimes in practice, and
the estimated variance could potentially inflate the type I error rate. To explore the
effect of using the estimated covariance matrix from the sample on the FWER, the case
of the two endpoints in one-sample test is studied through simulations. The observed
p-value is calculated using Z-statistic with the estimated variance, the correlation
is estimated from the sample data, denoted as ρˆ, and the equal critical values are
calculated from Eq. (2.4) with ρ replaced by ρˆ. Based on 100,000 simulations, the
FWER under the global null (Table 2.5) with the estimated variance and correlation is
controlled when the sample size is larger than 500 for a typical phase III trial, for which
FWER is critical. For a smaller sample size, around 60-100, an error rate inflation is
observed while is within the acceptant limit. However, since this is a typical sample
size for a phase II trial, for which FWER is not as critical as phase III trial, such a
small inflation should be acceptable. The FWER under other two configurations of
null hypothesis is shown in Appendix (Table F.1) and it is also well-controlled for
large sample size. Therefore, we recommend to apply the SPPM testing procedure in
the phase II/III trials when there is no information about the variance and correlation
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ahead.
We also evaluated the FWER under the global null for the three-hypothesis testing
with unknown covariance matrix. The critical values were obtained using the maximum
observed pairwise correlation. Due to the computational time, 10,000 replicates were
simulated and the results are in Table 2.6. FWER is inflated with the negative
correlation, however, the negative correlation among large number of hypothesis is a
rare case in practice. For the positive correlation, we observe the similar conclusion
about FWER as those of two-hypothesis testing.
Table 2.5: Familywise error rate under the global null using SPPM
procedure with the estimated covariance for two-hypothesis testing given
α = 0.025 (100,000 simulations).
N = 15 N = 60 N = 120 N = 500 N = 1000
ρ = −0.99 0.0414 0.0286 0.0267 0.0254 0.0245
ρ = −0.5 0.0401 0.0280 0.0259 0.0252 0.0247
ρ = 0 0.0400 0.0286 0.0257 0.0251 0.0243
ρ = 0.5 0.0389 0.0280 0.0261 0.0254 0.0248
ρ = 0.99 0.0357 0.0277 0.0259 0.0255 0.0245
Table 2.6: Familywise error rate under the global null using SPPM
procedure with the estimated covariance for three-hypothesis testing
given α = 0.025 (10,000 simulations).
N = 15 N = 60 N = 120 N = 500 N = 1000
ρ = −0.5 0.043 0.030 0.027 0.026 0.031
ρ = 0 0.032 0.031 0.027 0.023 0.022
ρ = 0.5 0.034 0.025 0.024 0.023 0.022
ρ = 0.99 0.036 0.026 0.026 0.022 0.024
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2.4 Real Data Application
In a dose-response study, the placebo or the control drug is generally included for
comparison, which naturally leads to the multiple testing problem. The application
of the SPPM testing procedure in a Phase III dose-response trial, in which dose-
response is based on the hypotheses testing and requires pre-specification of multiple
testing procedure, will be illustrated. A randomized, placebo-controlled study was
conducted to compare the overnight efficacy and plasma concentration-time profiles
of Armodafinil (150, 200, and 250 mg) in patients with chronic Shift Work Sleep
Disorder (SWSD). The primary endpoint was the change in Multiple Sleep Latency
Test (MSLT) from the baseline to the last visit. MSLT is an objective assessment
of sleepiness that measures the likelihood of falling asleep. The details of this trial
can be found at https://clinicaltrials.gov with identifier as NCT00236080. The
three individual hypotheses might be of interest:
H0i : µi − µc ≤ 0 vs. Hai : µi − µc > 0,
where µi (i = 1, . . . , 3) and µc are the true means of the change in MSLT from
baseline in the three Armodafinil treatment groups and the placebo group, respectively.
The procedure dealing with the multiple testing is required and parametric testing
procedure could be potentially more powerful by utilizing the known correlation among
the test statistics in this design. The measurements of change in MSLT from baseline
and one-sided p-values for the comparisons between treatment and placebo groups
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are in Table 2.7. The pooled estimate for variance as 19 was used (p-value from the
Bartlett’s test is 0.559). The correlation matrix of the test statistics is determined by
sample size and is:  1 0.499 0.4990.499 1 0.479
0.499 0.479 1
 ,
Therefore, the equal pairwise correlation as 0.499 is assumed in this case. The critical
values using the SPPM procedure are: α1 = α2 = α3 = 0.00182 and α4 = 0.00108 for
one-sided test significance level as 0.025.
Table 2.7: Multiple Sleep Latency Test change from baseline in 4
groups.
Armodafinil Armodafinil Armodafinil Placebo
250 mg/Day 200 mg/Day 150 mg/Day
Number of Participants 27 23 23 25
MSLT: Mean (SD) 3.7 (4.33) 3.7 (5.07) 2.7 (4.24) 1.1 (3.76)
p-value
(Treatment vs. Placebo) 0.016 0.020 0.102 -
With the Hommel and Dunnett step-up procedures introduced in the previous
section, we cannot reject any individual hypotheses and therefore fail to reject the global
intersection null hypothesis. The fixed sequence procedure, testing the doses from
highest to lowest, rejects both H1 and H2. With the SPPM procedure, we can reject
H1 because p1p2p3 = 3.16 × 10−5 < α4, p1p2 = 0.00031 < α1, p1p3 = 0.00162 < α1,
and p1 < α; we cannot reject H2 because p2p3 = 0.00199 > α2; and we cannot reject
H3 because p3 > α. Although the fixed sequence procedure rejects more hypotheses
in this setting, it requires the correctly specified testing order as mentioned before.
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The similar issue of specifying the underpowered groups happen to the 4A method,
too. However, SPPM doesn’t need any prior information and could reject H1.
2.5 Discussion
Multiplicity is an important issue in the planning, data analysis, and interpretation of
clinical trial studies. There are many testing procedures for such problem, that can
control the familywise error rate appropriately. However, a big challenge in multiple
testing is the lack of a test that is uniformly most powerful under different patterns of
correlation structure and the effect sizes. In this chapter, we reviewed some popular
multiple testing procedures, and propose a novel and efficient single-step progressive
parametric multiple testing procedure for normally distributed test statistics allowing
for the existence of correlation. The SPPM procedure constructs the testing by
controlling the upper bounds of products of local individual p1, . . . , pk. We derive the
cumulative probability function of test statistics in two- and three-hypothesis testing
framework and give the critical values numerically. The proposed procedure can also
be generalized to K-hypothesis testing (K ≥ 4), in which the K rejection rules are
specified as:
if ∩Kk=1 ∩Mkm=1 [(
∏
i∈ωmjk
pi) ≤ αjk], j = 1, 2, . . . , K, then reject Hj,
where ωmjk is the set of products of k p-values that include pj , and ωmjk hasMk = (
K−1
k−1 )
different elements. Each product term corresponds to a null configuration in the
closed set for Hk, and vice versa. For simplicity, we have αjk = αk, which means
the rejection rules are not differentiated among hypotheses. The critical values
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α1, α2, ..., αK are determined progressively as illustrated before: select α1 as α based
on the single hypothesis testing, then determine αk based on α1, α2, ..., α(k−1) under
the corresponding intersection hypothesis. For the large number of hypotheses and/or
strong correlation, the higher order of products of p-values are not needed practically
because those higher order of products are implicitly satisfied by the lower order
products, as also shown in Table 2.2. With the larger number of hypotheses, simulation
is more convenient than numerical integration to obtain the critical values.
In terms of power comparison, the step-up Dunnett and 4A methods have their
own strengths in some specific situations, however, our procedure can improve power
compared to other procedures in the most situations with the same direction of effect
sizes. The advantage of SPPM is prominent when the effect sizes are similar and
the correlation among test statistics is small or moderate. Although the power is
dependent on the pre-specified weight, the procedure is somewhat robust: for two
hypothesis testing with an equal or unequal effect sizes, the power still gains when
the weights are unequal (1-3 times difference) in some situations. Given the power
improvement as shown, the application of the proposed testing procedure for one
primary endpoint and multiple secondary endpoints is also promising, in which the
secondary endpoints are tested using the SPPM procedure after the test for the
primary endpoint is significant. In addition, we want to emphasize that when applying
the SPPM procedure, the critical values α′ks can be determined based on the clinical
importance of each individual hypothesis, or the goal of achieving higher power, or
finding a balance between these two conditions. Finally, the SPPM testing procedure
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is constructed based on the normal distribution, the application for other endpoints
could be challenging due to the unknown underlying distribution, and should be a
topic for future research.
In this chapter, we only derived the critical values numerically for three-hypothesis
testing with equal pairwise correlation, and we understand its limitation of usage. But
the more general situation with unequal correlations require further study and we
plan to work on this case in the near future. Although we have shown several different
adjustments of critical values to examine the power when the effect sizes greatly differ,
the optimal allocation of α according to the alternatives has not yet been investigated.
In the future, we intend to study how to design a testing procedure with the optimal
critical values if we have enough information about the means or treatment effects
and the correlation among hypotheses. Moreover, the adaptive design is another
important area for exploration since it allows us to adjust the allocation of α on
different hypothesis for consecutive stages based on the observed interim data, which
is especially useful when we have little knowledge about the effect sizes before the
study.
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Chapter 3
Multiple Primary Endpoints in Group
Sequential Design
3.1 Introduction
Group sequential designs (GSD) are clinical trials which allows interim looks with the
possibility of early terminations due to efficacy, harm or futility, which can reduce the
overall costs and timelines for the development of a new drug. However, repeated
looks of data could inflate the type I error rate, and the proper treatments to the
error inflation have been discussed widely. Simple group sequential approaches were
developed (Pocock, 1977; O’Brien and Fleming, 1979; Wang and Tsiatis, 1987) by
adjusting the critical values to control the type I error. Those approaches require the
pre-specified fixed number of equally spaced analyses and therefore lack in flexibility.
Lan and DeMets (Lan and DeMets, 1983) proposed an alternative method of using
α-spending functions to construct sequential boundaries, which has also been extended
to one-parameter family of α-spending functions in order to construct customized
designs (Kim and DeMets, 1987; Hwang et al., 1990), and to futility test of interim
analyses using type II error spending function (Pampallona et al., 2001). The error
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spending function approach has become popular because it allows unequally spaced
interim analyses and have room for unplanned interim looks or changing the interim
analyses on the condition of a little knowledge for treatment effects.
Most literature about group sequential designs focuses on a single endpoint, however,
the application of GSD to multiple endpoints has also received considerable attention.
Some research has been done to investigate the situation where the secondary endpoint
is tested only if the primary endpoint is significant in GSD (Hung et al., 2007; Glimm
et al., 2010; Tamhane et al., 2010). Glimm et al. (Glimm et al., 2010) and Tamhane
et al. (Tamhane et al., 2010) studied this problem, subject to a gatekeeping constraint,
using a GSD with K = 2 looks. Tamhane et al. (Tamhane et al., 2017) extend
to multiple looks (K > 2) in GSD. There also has been available work about the
multiplicity adjustment in the GSD with multiple co-primary endpoints (Jennison
and Turnbull, 1993; Cook and Farewell, 1994; Asakura et al., 2014; Cheng et al.,
2014), where the trial is designed to evaluate the efficacy on all the primary endpoints.
Cheng et al. (Cheng et al., 2014) studied the situation when all endpoints are claimed
beneficial at the same interim timepoint and showed that stopping boundaries for
the GSD with multiple co-primary endpoints should be the same as those for studies
with single endpoint. Furthermore, Asakura et al.(Asakura et al., 2014) independently
derived the power and sample size under the same situation, and also allowed that
the two endpoints achieved efficacy at any interim timepoint. The main focus of this
chapter is another interesting topic for the GSD with multiple primary endpoints,
in which the trial is to evaluate whether at least one of the endpoints is significant.
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In this study design, two multiplicity issues arise: one is from repeated testing at
different stages and another is from multiple endpoints. Therefore, the appropriate
adjustments must be made to control the Type I error rate. Previous work has been
done to explore the field using different approaches (Tang et al., 1989; Tang and Geller,
1999; Kosorok et al., 2004; Maurer and Bretz, 2013). Tang et al. (Tang et al., 1989)
used O’Brien’s generalized least squares statistics in the group sequential design which
combines the information from multiple endpoints into one test statistic. Jennison
and Turnbull (Jennison and Turnbull, 1991) discuss a method based on χ2 and F test
statistics, where the trial is designed to test an overall effect across the endpoints, but
does not necessarily evaluate the effect on any specific endpoint. Kieser et al. (Kieser
et al., 1999) recommended a method combining multiple testing with interim analyses
for the rejection of all endpoints, in which the test of multiple endpoints is considered
at each stage and the corresponding adjustments are considered in the same way as
classical design, like a priori ordered hypotheses or the Bonferroni-Holm method.
Tang and Geller (Tang and Geller, 1999) applied the closure principle using a global
testing procedure for multiple primary endpoints where group sequential monitoring
is planned, in which the single endpoint hypothesis could not been rejected even the
global hypothesis is rejected. They have shown that if a group sequential procedure
at level α is tested for each intersection hypothesis, then the application of the closure
principle can lead to a test procedure that controls the FWER at level α. However,
the power of Tang and Geller method was not evaluated thoroughly in their or other
work. Ye et al. (Ye et al., 2013) considered the significance level allocation problem
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and proposed a group sequential Holm procedure for multiple primary endpoints,
which is a special case of group sequential graphical procedure (Maurer and Bretz,
2013). Later, Rosenblum et al. (Rosenblum et al., 2016) improves this procedure by
leveraging the covariance among statistics for different populations in the adaptive
enrichment designs, which are correlated if the populations overlap.
However, some of the above approaches deal with the two multiplicity problems
somewhat separately, our purpose here is to show that the combination of multiple
endpoint and repeated interim analyses can lead to a more powerful design. Via the
multivariate normal distribution, we propose a method that allows for simultaneously
consideration of interim analyses and all clinical endpoints with the known correlation.
The stopping boundaries of the proposed procedure can be obtained through numerical
integration. The new approach is derived from the closure principle, thus it can control
type I error rate strongly. The procedure was also extended to allow the α reallocation
to improve the power of rejecting both endpoints for some study designs under
the inspiration of the work of (Ye et al., 2013) and (Maurer and Bretz, 2013). In
this chapter, we also studied the power performance of Tang and Geller (T&G)
method under different scenarios, and found it provides extremely low power in group
sequential test with multiple endpoints when the effect sizes differ a lot. Through
power comparison among various methods by simulation study, our procedure can be
favorable in terms of power or the average sample size in some conditions.
This chapter evolves as follows. We begin with a description of methods using
multivariate distribution for group sequential design with multiple endpoints, followed
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by the details of familywise error rate (FWER) control. The reallocation of significance
level are discussed then. The extensive simulation studies demonstrate that the
proposed approach is more powerful given some specific study designs. The Discussion
section concludes this chapter with a short summary.
3.2 GSD with Multiple Primary Endpoints using Multivari-
ate Distribution
In this section, we introduce the method for the group sequential design with multiple
primary endpoints using the multivariate normal distribution (GSMulti). For simplicity,
let us start with a simple case, that a one-arm, two-stage and two primary normal
endpoints clinical trial with known covariance matrix. Although the simple case is
illustrated here, the approach is also able to used in the two-arm design because the
joint distribution of test statistics is similar as in the one-arm design. Let Xi = (
Xi1
Xi2
)
indicate the two endpoint responses for individual i, which follows a bivariate normal
distribution N2((
µ1
µ2 ),
(
1 ρ
ρ 1
)
), where the variance of endpoint response is assumed as
1 without losing any generalization, and ρ is the known correlation between two
endpoints. Let Hk and H¯k denote the null and alternative hypotheses of interest for
the kth endpoint, respectively: Hk : µk ≤ 0 vs. H¯k : µk > 0 (k = 1, 2). The aim of the
trial is to assess the treatment effect on either endpoint X1 or X2 or both. Then, the
global hypothesis is in the union-intersection testing framework:
H0 : H1 ∩H2 vs. Ha : H¯1 ∪ H¯2. (3.1)
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3.2.1 Stopping Boundaries
In a two-stage group sequential design, define τ as the information time, which is the
amount of statistical information available in the interim analysis. In general, τ is
based on the Fisher information, and is the ratio of the information in the interim
analysis and the maximum information to be collected through the study. For the
normal distributed endpoints, τ = n1
N
, where n1 and N are the cumulative sample size
in stage 1 and stage 2. The GSMulti test rules for the union-intersection hypothesis
are then formulated as:
• At stage 1, if Z1(τ) > c1(τ) or Z2(τ) > c2(τ), the trial is stopped and reject H0;
otherwise, go on to the 2nd stage;
• At stage 2, if Z1(1) > c1(1) or Z2(1) > c2(1), the trial is stopped and reject H0;
otherwise, fail to reject H0,
where Zk(τ) =
∑n1
i=1Xik√
n1
and Zk(1) =
∑N
i=1Xik√
N
are the interim and final test statistics for
the kth endpoint, and ck(τ) and ck(1) are the stopping boundaries for the kth endpoint
in the corresponding stage, which should satisfy the following equations:
sup Pr(Z1(τ) > c1(τ) ∪ Z2(τ) > c2(τ)|H0) = pi1 (3.2)
sup Pr((Z1(τ) ≤ c1(τ) ∩ Z2(τ) ≤ c2(τ)) ∩ (Z1(1) > c1(1) ∪ Z2(1) > c2(1))|H0)) = pi2,
(3.3)
where pi1 + pi2 = α. Here, Hk is rejected if Zk(τ) ≥ ck(τ) in the interim analysis or
Zk(1) ≥ ck(1) given the trial continues to the final stage. The Eqs. (3.2) and (3.3)
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appear to control error rate only under the global null, however, the proposed group
sequential procedure above also strongly controls the FWER at level α because
it is a closed testing procedure. To elaborate this, consider the closed family set
{H1, H2, H1 ∩ H2}. The closure principle states as a hypothesis is rejected only if
all intersection hypotheses containing this hypothesis are rejected, and testing each
intersection hypothesis using a local level α test. For example, H1 is rejected only if
H1 and H1 ∩H2 are both rejected at level α test. The proposed procedure ensures a
level α test for the single hypothesis as well, say H1, because:
sup Pr(Z1(τ) > c1(τ) ∪ (Z1(τ) ≤ c1(τ) ∩ Z2(τ) ≤ c2(τ) ∩ Z1(1) > c1(1))|H1)
≤ sup Pr(Z1(τ) > c1(τ) ∪ Z1(1) > c1(1)|H1) ≤ α.
Similarly, we can show that for H2 as well. Therefore, the proposed procedure GSMulti
is a closed testing procedure, and the stopping boundaries c′s serve as the local stopping
boundary of level α test for H1 and H2, respectively, which also implies that our
procedure has consonant property (Gabriel, 1969).
With regard to the stopping boundaries, it can be seen that Eqs. (3.2) and (3.3)
achieve the maximum in the null parameter space when µ1 = µ2 = 0, which simplify
the two equations above at the border of the global null. Then we can utilize the
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multivariate normal (MVN) distribution:
Z1(τ)
Z2(τ)
Z1(1)
Z2(1)
 ∼ N4


√
n1µ1√
n1µ2√
Nµ1√
Nµ2
 ,

1 ρ
√
τ
√
τρ
ρ 1
√
τρ
√
τ√
τ
√
τρ 1 ρ√
τρ
√
τ ρ 1

 (3.4)
under µ1 = µ2 = 0 to calculate the stopping boundary c
′s at level α test using
numerical integration, given a reasonable value of pi1. Specifically, one can choose the
stopping boundaries for one endpoint and then calculate c′s for another one. Or the
ratio between two stopping boundaries could be assigned ahead based on the clinical
importance or the relative magnitude of effect sizes. The corresponding R function
with an example is provided in Appendix G. Note the equal stopping boundaries
reduces the procedure to the Dunnett-type adjustment, and when only one endpoint
is involved, the proposed method is reduced to the standard error spending approach.
To illustrate the proposed procedure above, consider a two-stage group sequential
design with an interim analysis planned at τ = 0.5, and two correlated normal primary
endpoints E1 and E2 (ρ = 0.5). Then, the stopping boundaries are c1(τ) = c2(τ) = 2.558
and c1(1) = c2(1) = 2.328 given one-sided level of significant α = 0.025 and the error
spent in the interim pi1 = 0.01. Suppose the test statistics in the interim analysis
are: (1) z1(τ) = 3.04 and z2(τ) = 2.23; (2) z1(τ) = 2.06 and z2(τ) = 2.32. For scenario
(1), the trial is stopped in the interim and H0 is rejected because of the rejection of
E1 (z1(τ) > 2.558). For scenario (2), the trial will continue to the final stage since
no test statistic is larger than 2.558. Suppose the test statistics in the final stage for
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scenario (2) are: (2.1) z1(1) = 2.43 and z2(1) = 2.59; (2.2) z1(1) = 2.13 and z2(1) = 2.29.
For scenario (2.1), the trial is stopped with the rejection of H0 because at least one
endpoint is rejected (both z1(1) and z2(1) are larger than 2.328). For scenario (2.2), the
trial is stopped but H0 cannot be rejected since no test statistic exceeds the stopping
boundary 2.328.
When the alternative hypothesis of (3.1) is true, the power of the procedure is
formulated as:
Pr((Z1(τ) > c1(τ) ∪ Z2(τ) > c2(τ))
∪ ((Z1(τ) ≤ c1(τ) ∩ Z2(τ) ≤ c2(τ)) ∩ (Z1(1) > c1(1) ∪ Z2(1) > c2(1)))|Ha)
= Pr((Z1(τ) > c1(τ) ∪ Z2(τ) > c2(τ)) ∪ (Z1(1) > c1(1) ∪ Z2(1) > c2(1))|Ha),
which is the probability of rejecting the global null H0, and is equivalent to the power
of rejecting at least one null hypothesis because our procedure is based on the closure
principle and the stopping boundaries can control FWER strongly. This probability
is also referred to as “disjunctive power” (Senn and Bretz, 2007).
3.2.2 Extension
For a group sequential design with J stages and K primary endpoints (J − 1 interim
analysis and a final analysis), the GSMulti test rules are:
• At stage 1, if at least one Zk(τ1) > ck(τ1), the trial is stopped and reject H0; otherwise,
go on to the 2nd stage;
• At stage j, j = 2, . . . , J − 1, if at least one Zk(τj) > ck(τj), the trial is stopped and
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reject H0; otherwise, go on to the j + 1 stage;
• At the final stage J , if at least one Zk(1) > ck(1), the trial is stopped and reject H0;
otherwise fail to reject H0,
where Zk(τj) and ck(τj) are the test statistic and the stopping boundary for k
th endpoint
in the stage j with the information time as τj , respectively, k = 1, . . . , K, j = 1, . . . , J
and τJ = 1. The joint distribution of Zk(τj)’s follows multivariate normal distribution:
Z1(τ1)
...
ZK(τ1)
...
Z1(τj)
...
ZK(τj)
...
Z1(1)
...
ZK(1)

∼MVN


√
n1µ
...√
njµ
...√
Nµ

JK×1
,

Σ11 . . . Σ1j . . . Σ1J
...
Σj1 . . . Σjj . . . ΣjJ
...
ΣJ1 . . . ΣJj . . . ΣJJ

JK×JK
 ,
(3.5)
where µ = (µ1, . . . , µK)
T , Σjj represents the correlation among different endpoints
at jth stage and they are all in the same form, with the diagonal element as 1 and
off-diagonal elements as ρkk′ . The off-diagonal block matrix Σjj′ = Σj′j =
√
τj
τj′
Σjj,
j, j′ = 1, . . . , J and j > j′. Then the stopping boundaries c’s can be obtained using
Formula (3.5) by solving:
sup Pr(∪Kk=1 ∪J
′
j=1 Zk(τj) > ck(τj)|H0) = α(J ′), J ′ = 1, . . . , J,
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α(J ′) is nondecreasing function with α(0) = 0 and α(J) = α. The complexity of
computational cost increases as the increase in the number of stages and the number
of primary endpoints.
3.2.3 Group Sequential Design with Unknown Variance
Thus far, we assumed the variance of two endpoints are known and the stopping
boundaries were derived under such an assumption. However, it is unlikely to know the
true variance sometimes. For the confirmatory clinical trials, the asymptotic normal
could be satisfied by the large sample size the stopping boundaries from Z-statistics
above can be implemented, but the FWER will be inflated with the asymptotic
distribution when the sample size is small. Hence, with unknown population variance
we consider the T-statistics Tk(τ) =
∑n1
i=1Xik/n1
sk(τ)
and Tk(1) =
∑N
i=1Xik/N
sk(1)
, where sk(τ)
and sk(1) are the sample variances of each endpoint in the interim and final analyses,
respectively. It is hard to derive the joint distribution of the T-statistics in the GSD,
and the corresponding tk’s might require the extensive simulations to obtain. Here,
we applied an approach for the case of unknown covariance matrix, in which the
stopping boundaries in Section 2.1 can be used directly and no simulations need to
be conducted. In the GSD with a single endpoint, Proschan et al. (Proschan et al.,
2006) proposed to apply the inverse normal method to yield the type I error rate
exactly at level α. For the multiple endpoints problem, the FWER can be shown
to achieve maximum at µ1 = µ2 = 0 under t-distribution by the similar logic used
for normal distribution. Thus, the FWER is controlled and evaluated at the worst
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case of µ1 = µ2 = 0. Here, we employ the inverse normal method in the multivariate
case. The idea is straightforward: Tk,j is the stage-wise T-statistics computed on the
incremental samples between stage j − 1 and stage j for the endpoint k, with the
associated one-sided p-values pk,j. The inverse normal method uses the transformation
Φ−1(1− pk,i) to convert p-values to standard normal. Then, the cumulative z-score is:
Uk,j =
j∑
i=1
wk,jiΦ
−1(1− pk,i), (3.6)
where wk,11 = 1, wk,21 =
√
n1
N
and wk,22 =
√
N−n1
N
for the two-stage group sequential
design; and Uk,j has the standard normal distribution under µ1 = µ2 = 0. The
correlation of inverse normal z-scores for two endpoints is roughly equal to ρ, because
of the approximately invariant property of correlation given the variance is “small”
under the transformation by a monotonically increasing or decreasing function (Zaykin
et al., 2002):
Cor(g(X), g(Y )) =
Cov(g(X), g(Y ))√
V ar(g(X))V ar(g(Y ))
≈ g
′(µ)2Cov(X, Y )√
g′(µ)4V ar(X)V ar(Y )
= Cor(X, Y ).
Then it is easy to see that
(U1,1
U2,1
U1,2
U2,2
)
is approximately distributed as:
N4


0
0
0
0
 ,

1 ρ
√
τ
√
τρ
ρ 1
√
τρ
√
τ√
τ
√
τρ 1 ρ√
τρ
√
τ ρ 1

 ,
56
which has the same distribution as
(Z1(τ)
Z2(τ)
Z1(1)
Z2(1)
)
in Section 2.1. Therefore, the stopping
boundaries derived above can be applied to z-score of Eq. (3.6). Table 3.1 illustrates
that the inverse normal method with approximately assumed correlation has a remark-
able control of the FWER when the variance is unknown, under different sample sizes
and known correlations between endpoints (100,000 simulations).
Table 3.1: Familywise error rate of inverse normal method in multi-
variate case given α = 0.025 (100,000 simulations).
Maximum Sample Size ρ = 0.25 ρ = 0.5 ρ = 0.75
10 0.0258 0.0258 0.0260
20 0.0251 0.0252 0.0260
30 0.0252 0.0252 0.0247
50 0.0256 0.0256 0.0255
80 0.0254 0.0254 0.0251
100 0.0255 0.0256 0.0259
Error spent in the interim pi1 = 0.0026.
3.2.4 Group Sequential Design with Unknown Correlation
Since the correlation ρ is important in determining the stopping boundaries and
utilization of correlation is one of the reasons that the proposed approach can improve
the power, it deserves more explorations and discussions:
(1) When a hypothesis test involves a correlation-dependent critical value c(ρ), we
can write the decision rule in an equivalent form with constant critical value. This is
because T > c(ρ) is equivalent to T ∗ = T
c(ρ)
z1−α > z1−α, and z1−α is independent of
the correlation ρ.
(2) On the other hand, we can rewrite commonly used T-test in a test with a
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standard-deviation-dependent critical value. That is, T = X¯
σˆ
> t1−α,n is equivalent to
Z = X¯
σ
> c(σˆ) = σˆ
σ
t1−α,n, where assumed true σ can be any positive number. In this
way, c(σˆ) becomes an observed data-dependent critical value.
(3) When the standard deviation σ is unknown, the critical values for T-test and Z-test
are practically the same for large sample size, but it does not mean the standard
deviation is estimated correctly every time. Nevertheless, as long as the error rate is
controlled under the repeated experiments, replacing Z-test for T-test is acceptable.
In clinical trials, sample size of 30 is a tipping point for using Z-test. In terms of
the proposed method, the inaccurate correlation estimate will impact the value of
c compared to c(ρ). Analogously, the proposed method using estimated correlation
would be proper if it controls error rate under repeated experiments.
Due to reasons (1) to (3), we use simulations to check the type I error rate of
the proposed method for various sample size when the correlations based on the first
stage observations are used to determine the critical value. The results are shown in
Table 3.2. As expected, the standard deviation of the estimated correlation is large
when the sample size is small, and drops a lot when N interim is 30. The familywise
error rate is inflated but still within the acceptable limit. In addition, when the error
spent in the first stage pi1 increases, FWER will increases too. For example, the error
rate is 0.0286 under the design of ρ = 0, τ = 0.5 and pi1 = 0.014. However, the Z-test,
instead of T-test when the sample size is 30, makes the type I error rate as large as
0.0298 for one-sided test at significance level of α = 0.025. Therefore, we consider our
proposed procedure even when the observed correlations are used is more stable and
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robust than using Z-test in place of T-test. Based on those simulation results, when
the correlation is unknown in practice, we can use estimated correlation in the interim
to derive the stopping boundary. In other words, we first decide the error spent in the
first stage, then based on the error-spending function and the observed correlation
coefficient to calculate the stopping boundary on Z-scale.
Table 3.2: Familywise error rate with the stopping boundaries from
the estimated correlation under different sample size given τ = 0.5,
pi1 = 0.0026 and α = 0.025 (100,000 simulations).
N (N interim)* Correlation ρ Estimated Correlation ρˆ (SDρˆ)
$ FWER
20 (10)
0 -0.002 (0.333) 0.0259
0.25 0.236 (0.317) 0.0249
0.5 0.478 (0.267) 0.0254
0.75 0.730 (0.172) 0.0253
40 (20)
0 0.000 (0.230) 0.0242
0.25 0.244 (0.217) 0.0251
0.5 0.490 (0.178) 0.0251
0.75 0.740 (0.110) 0.0249
60 (30)
0 -0.001 (0.186) 0.0252
0.25 0.246 (0.175) 0.0252
0.5 0.494 (0.142) 0.0251
0.75 0.745 (0.086) 0.0251
80 (40)
0 0.000 (0.162) 0.0248
0.25 0.248 (0.151) 0.0252
0.5 0.495 (0.122) 0.0249
0.75 0.746 (0.073) 0.0249
100 (50)
0 0.000 (0.143) 0.0247
0.25 0.247 (0.134) 0.0248
0.5 0.496 (0.108) 0.0256
0.75 0.746 (0.065) 0.0244
*: Total sample size (Sample size in the interim analysis);
$: The correlation estimation is based on the observations collected in the interim.
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3.2.5 GSD with Multivariate Distribution using Reallocating Significance
Level
When multiple primary endpoints are involved in a study, the situation might occur
that some primary endpoints are claimed efficiency at the interim analyses, while the
trial still needs to continue to evaluate other primary endpoints, especially in the
oncology trials. If the stopping boundaries from the standard approach introduced
above are used for the other not-yet-rejected endpoints in the following analyses, the
power for detecting on all endpoints, which is also referred to as “conjunctive power”
(Senn and Bretz, 2007), will be limited. However, by using the idea of reallocating
the significance levels (Bretz et al., 2009; Burman et al., 2009), a more powerful
procedure can be constructed. The concept of the significance level reallocation is
straightforward. Consider a clinical trial with two primary endpoints, the significance
level from the rejected hypothesis for one endpoint will be recycled to the not-yet-
rejected endpoint. The question for the application in a group sequential setting is
how to allocate the significance level to the interim analyses for the not-yet-rejected
endpoints. Ye et al. (Ye et al., 2013) proposed two approaches for reallocation in
this situation: (1) reallocating the significance level from the rejected endpoints to
all analyses (including all the interim and final analyses) for the not-yet-rejected
endpoints, and (2) reallocating the significance level from the rejected endpoint only
to the final analysis for the not-yet-rejected endpoints. Xi and Tamhane (Xi and
Tamhane, 2015) also considered to recycle the significance level from the rejected
endpoint to the later pre-specified interim.
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Motivated by the previous work, we here consider the reallocation of the full
significance level from the rejected endpoints to all of the analyses for the other
endpoints. Note that if one endpoint is rejected at interim analysis, we regard it
as rejected for the following analyses. The adjusted stopping boundaries are always
smaller or equal to the original stopping boundaries, and this restriction on the
boundaries can ensure the consonant property (Gabriel, 1969). The alpha reallocation
strategy aims at improving the conjunctive power of rejecting all the endpoints,
however, the disjunctive power will remain the same as the standard approach. The
two-stage group sequential design with two primary endpoints again are used for an
illustration here. First, the two sets of stopping boundaries are calculated: one is
based on Eqs. (3.2) and (3.3) considering two endpoints and the other is for a single
endpoint. For example, suppose such a GSD is conducted with the information time
τ as 0.5, the correlation between endpoint E1 and E2 as 0.5 and the total significance
level α as 0.025. The equal stopping boundaries for two endpoints and pi1 =0.01 are
used: c(τ) =2.558 and c(1) =2.328. The stopping boundaries for a single endpoint at
α = 0.025 are 2.326 and 2.076 using error spending function with pi1 =0.01 (Kim and
DeMets, 1987; Jennison and Turnbull, 1999). If the observed test statistic for E1 in
the interim is larger than the stopping boundary 2.445, then the test for E2 is tested
against 2.326 at the interim analysis and 2.076 in the final stage.
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3.3 Simulation Study of Power Comparisons
To explore the sample size of the group sequential design described above, we conducted
the simulation study and Table 3.3 shows the maximum sample size required with the
equal stopping boundaries to reach the 90% power of detecting the effect size of 0.2
for at least one endpoint in the two-stage GSD using information time τ = 0.5 and
pi1 = 0.0026. In the meantime, the maximum sample size of 264 is needed to achieve
90% power of detecting the effect size 0.2 for GSD with a single endpoint using τ = 0.5
and O’Brien-Fleming boundaries (O’Brien and Fleming, 1979) (pi1 = 0.0026). From
Table 3.3, considering the two primary endpoints with the same effect sizes can gain
the power compared to the single endpoint. Besides, ignoring the correlation between
endpoints will lead to the overestimated power and the inaccurate study design.
Table 3.3: Maximum sample size for two-stage GSD with two primary
endpoints to reach 90% power at one-sided overall significance level
α = 0.025.
Correlation ρ Maximum sample size
0 187
0.25 206
0.5 225
0.75 245
µ1 = µ2 = 0.2 and pi1 = 0.0026.
To evaluate the performance of the proposed method, we compare GSMulti with
the Bonferroni approach and T&G method through extensive simulation study under
different situations. The Bonferroni approach in GSD with multiple endpoints is
splitting α among the endpoints (
∑k
i=1 αi = α) each with an independent general
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group sequential procedures, for example, applying O’Brien Fleming or Pocock Bound-
ary for each endpoint. We first used the unweighted Bonferroni approach with OBF
boundary (GSD OBF) for comparisons to protect early stopping with small fraction
of information against making a decision error that the endpoint is significant when it
is not in fact. For T&G and GSMulti methods, the error spent in the first stage pi1
is set to 0.0014 to make the power comparable among those three approaches. Due
to the flexibility of GSMulti method about the unequal stopping boundaries for each
endpoint, we also assess the power of unbalanced stopping boundaries (GSMulti unbal:
c1(τ) = 1.12c2(τ) and c1(1) = 1.12c2(1)), and the weighted Bonferroni approach with
2α1 = α2 (GSD OBF w) is included as well to show the power performance parallel
to GSMulti unbal, where the Z-scale stopping boundary ratio for GSD OBF w is
the same as the ratio for GSMulti unbal when α = 0.025. We simulated a hypo-
thetical one-arm, two-stage and two primary normal endpoints (E1 and E2) group
sequential design with known variance-covariance matrix. Total of 200 individuals
were involved and the interim happened at the information time τ of 0.5. Four
different values of correlation (ρ = 0, 0.25, 0.5, or 0.75) and four sets of effect sizes
((µ1, µ2) = (−0.1, 0.2), (0.05, 0.2), (0.1, 0.2), or (0.2, 0.2)) were evaluated for power with
the significance level α as 0.025. We performed 10,000 simulations for each scenario.
The power for each endpoint at the final analysis and the disjunctive power of
rejecting at least one endpoint at the interim and final analyses were recorded in
Table 3.4. T&G method had unbeatable advantage when both endpoints have large
effect sizes, however, the power dropped dramatically when one endpoint has smaller
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effect, which is expected due to nature of the global test used by T&G method.
The better performance between T&G method and the proposed GSMulti procedure
depends on the effect sizes, sample size and correlation between endpoints. To show
the situation that GSMulti outperforms, the R function is provided in Appendix I for
the investigators to find the best cases for GSMulti given sample size and correlation.
The difference in power between the standard GSMulti method and GSD OBF was
not noticeable when the correlation is small since the GSMulti method is the same as
the unweighted Bonferroni approach when the correlation is 0. With the increasing
correlation, the GSMulti method outperformed the naive Bonferroni approach by
improving 2% power in general via incorporating the correlation information. In
practice, it is possible that the stopping boundaries for two endpoints are unequal
because of the difference in clinical importance and/or the effect size. When comparing
between the two GSMulti procedures with the unequal effect sizes, GSMulti unbal
had more power for E2 as a result of relative smaller stopping boundaries, accordingly
improved the disjunctive power of rejecting at least one endpoint. However, the
advantage using unequal stopping boundaries diminishes when the effect sizes are
the same. For example, the power of GSMulti was 1% higher than GSMulti unbal
under the situation of ρ = 0 and (µ1, µ2) = (0.2, 0.2). The comparisons highlights
the advantages of using the unequal stopping boundaries and implies that the power
of study design can be beneficial from the unbalanced alpha allocation according to
the prior knowledge about the effect sizes. Additionally, the weighted Bonferroni is
better than unweighted one in some situation as expected, but it is still worse than
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GSMulti unbal when the correlation exists. The same power pattern among different
approaches is shown with pi1 = 0.0144 and GSD Pocock (see Table H.1 in Appendix H).
To directly visualize the performance of different methods in terms of sample size, we
compared the maximum sample size (MSS) and average sample size (ASS) as well.
We also provided the fixed sample study design with two primary endpoints using the
flexible fixed-sequencing test (Huque and Alosh, 2008) as benchmarks for comparisons.
For each method, the maximum sample size was determined to ensure 90% disjunctive
power to detect at least one endpoint effect, and the average sample size was obtained
thereafter. The results are presented in Table 3.5. The comparisons in the sample
size between GSMulti and GSD OBF were consistent as the power comparisons in
Table 3.4, with GSMulti having smaller MSS and ASS and the savings in the sample
sizes were more prominent when the correlation between two endpoints is strong. The
MSS and ASS of T&G method were unfavorably high for the case of the smaller
effect size in one endpoint. For the same effect sizes (µ1 = µ2 = 0.2), the GSMulti
method provided larger MSS but smaller ASS than the fixed sample design because of
the flexibility of stop in the interim. With the differential effect sizes, the advantage
of group sequential design is more outstanding with similar or slightly smaller MSS
especially for the GSMulti method.
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Table 3.4: Power comparisons given n = 200, µ2 = 0.2, α = 0.025 and
interim time τ = 0.5 (10,000 simulations).
Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Disjunctive Power§
ρ = 0
-0.1
GSMulti 0 0.718 0.718 (0.113+0.605)
GSMulti unbal 0 0.752 0.752 (0.144+0.609)
GSD OBF 0 0.717 0.717 (0.114+0.603)
GSD OBF w 0 0.752 0.752 (0.147+0.605)
Tang&Geller 0 0.168 0.169 (0.010+0.159)
0.05
GSMulti 0.056 0.716 0.735 (0.116+0.619)
GSMulti unbal 0.041 0.751 0.764 (0.145+0.620)
GSD OBF 0.055 0.715 0.734 (0.118+0.616)
GSD OBF w 0.040 0.751 0.764 (0.148+0.616)
Tang&Geller 0.103 0.650 0.704 (0.109+0.595)
0.1
GSMulti 0.186 0.710 0.775 (0.126+0.649)
GSMulti unbal 0.143 0.748 0.791 (0.150+0.641)
GSD OBF 0.184 0.709 0.773 (0.128+0.645)
GSD OBF w 0.141 0.748 0.791 (0.154+0.637)
Tang&Geller 0.299 0.747 0.853 (0.193+0.660)
0.2
GSMulti 0.654 0.649 0.923 (0.216+0.707)
GSMulti unbal 0.583 0.705 0.919 (0.212+0.707)
GSD OBF 0.653 0.647 0.923 (0.220+0.703)
GSD OBF w 0.58 0.704 0.919 (0.217+0.702)
Tang&Geller 0.808 0.801 0.979 (0.442+0.538)
ρ = 0.25
-0.1
GSMulti 0 0.722 0.722 (0.113+0.609)
GSMulti unbal 0 0.758 0.758 (0.145+0.613)
GSD OBF 0 0.719 0.719 (0.114+0.605)
GSD OBF w 0 0.755 0.755(0.148+0.607)
Tang&Geller 0 0.145 0.145 (0.008+0.137)
0.05
GSMulti 0.052 0.720 0.730 (0.115+0.614)
GSMulti unbal 0.037 0.758 0.763 (0.146+0.617)
GSD OBF 0.051 0.717 0.726 (0.117+0.609)
GSD OBF w 0.035 0.754 0.759 (0.148+0.611)
Tang&Geller 0.104 0.587 0.609 (0.080+0.529)
0.1
GSMulti 0.179 0.713 0.756 (0.124+0.631)
GSMulti unbal 0.134 0.754 0.779 (0.150+0.629)
GSD OBF 0.176 0.710 0.752 (0.126+0.626)
GSD OBF w 0.131 0.751 0.775 (0.152+0.623)
Tang&Geller 0.298 0.707 0.766 (0.136+0.631)
0.2
GSMulti 0.655 0.651 0.895 (0.205+0.690)
GSMulti unbal 0.58 0.711 0.894 (0.204+0.690)
GSD OBF 0.653 0.647 0.894 (0.208+0.686)
GSD OBF w 0.576 0.707 0.891 (0.208+0.683)
Tang&Geller 0.802 0.799 0.947 (0.323+0.624)
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Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Disjunctive Power§
ρ = 0.5
-0.1
GSMulti 0 0.730 0.730 (0.114+0.616)
GSMulti unbal 0 0.764 0.764 (0.147+0.617)
GSD OBF 0 0.720 0.720 (0.115+0.605)
GSD OBF w 0 0.756 0.756 (0.148+0.608)
Tang&Geller 0 0.131 0.131 (0.007+0.124)
0.05
GSMulti 0.049 0.728 0.732 (0.116+0.616)
GSMulti unbal 0.032 0.763 0.765 (0.147+0.618)
GSD OBF 0.046 0.718 0.722 (0.116+0.606)
GSD OBF w 0.03 0.756 0.758 (0.149+0.609)
Tang&Geller 0.105 0.527 0.533 (0.062+0.470)
0.1
GSMulti 0.176 0.723 0.745 (0.121+0.624)
GSMulti unbal 0.128 0.761 0.772 (0.150+0.622)
GSD OBF 0.167 0.714 0.735 (0.122+0.613)
GSD OBF w 0.12 0.754 0.764 (0.151+0.613)
Tang&Geller 0.299 0.666 0.690 (0.105+0.585)
0.2
GSMulti 0.668 0.665 0.866 (0.191+0.675)
GSMulti unbal 0.588 0.726 0.864 (0.191+0.673)
GSD OBF 0.660 0.655 0.860 (0.192+0.668)
GSD OBF w 0.577 0.719 0.858 (0.193+0.665)
Tang&Geller 0.797 0.793 0.903 (0.248+0.656)
ρ = 0.75
-0.1
GSMulti 0 0.744 0.744 (0.120+0.624)
GSMulti unbal 0 0.777 0.777 (0.152+0.624)
GSD OBF 0 0.722 0.722 (0.116+0.606)
GSD OBF w 0 0.756 0.756 (0.152+0.604)
Tang&Geller 0 0.118 0.118 (0.006+0.111)
0.05
GSMulti 0.045 0.744 0.744 (0.120+0.624)
GSMulti unbal 0.027 0.777 0.777 (0.152+0.624)
GSD OBF 0.039 0.722 0.722 (0.116+0.606)
GSD OBF w 0.023 0.756 0.756 (0.152+0.604)
Tang&Geller 0.105 0.474 0.474 (0.049+0.425)
0.1
GSMulti 0.176 0.742 0.747 (0.122+0.625)
GSMulti unbal 0.123 0.776 0.778 (0.153+0.625)
GSD OBF 0.156 0.720 0.725 (0.119+0.606)
GSD OBF w 0.106 0.756 0.757 (0.152+0.605)
Tang&Geller 0.302 0.618 0.622 (0.083+0.538)
0.2
GSMulti 0.697 0.692 0.836 (0.177+0.659)
GSMulti unbal 0.608 0.752 0.834 (0.179+0.655)
GSD OBF 0.673 0.672 0.818 (0.172+0.647)
GSD OBF w 0.582 0.732 0.815 (0.177+0.638)
Tang&Geller 0.793 0.794 0.856 (0.196+0.660)
*: pi1 = 0.0014; §: Disjunctive power at the interim + Disjunctive power at
the final;
GSMulti: c1(τ) = c2(τ) and c1(1) = c2(1); GSMulti unbal: c1(τ) = 1.12c2(τ) and
c1(1) = 1.12c2(1).
GSD OBF: α1 = α2; GSD OBF w: 2α1 = α2.
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Table 3.5: Maximum sample size and average sample size comparisons
given power of 90%, ρ = 0.5, µ2 = 0.2, pi1 = 0.0014, α = 0.025 and interim
time τ = 0.5 (10,000 simulations).
GSMulti* GSD OBF* Tang&Geller* Fixed sample
µ1 = 0.05 304/269 310/273 506/445 306/306
µ1 = 0.1 298/264 304/268 352/309 300/300
µ1 = 0.2 224/194 228/201 198/174 220/220
*: pi1 = 0.0014.
We evaluated the GSMulti method using reallocating significance level (GSMulti v)
introduced in Section 3.2.5 by comparing the conjunctive power of rejecting both
endpoints with the standard GSMulti method and the graphical group sequential
procedure (Maurer and Bretz, 2013) under the FWER well-controlled. The same
simulation parameters as above were used here. For GSMulti v, the error spending
function with pi1 = 0.0014 will be used for the remaining endpoint if one endpoint
is significant using the stopping boundaries from GSMulti method. The power of
detecting the significant effect for endpoints E1 and E2 respectively and the conjunctive
power were shown in Table 3.6. GSMulti v was more powerful than GSMulti in all
the simulated situations, which had more power at both the interim and final analyses
because α reallocation led to the updated stopping boundaries. Comparisons of the
overall conjunctive power between GSD graphic and GSMulti v does not show the
distinguishable difference, because they both exhaust α as much as possible and the
advantage of GSMulti v considering correlation does not play a significant role on
the conjunctive power when the reallocating significance level happens. However,
GSMulti performs better than the graphic group sequential procedure in terms of
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the disjunctive power as demonstrated above. The similar power comparisons and
analogous conclusions can be found in Table H.2 (see Appendix H) for α reallocation
procedures with pi1 = 0.0144.
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Table 3.6: Power of rejecting both endpoints simultaneously given
n = 200, µ2 = 0.2, α = 0.025 and interim time τ = 0.5 (10,000
simulations).
Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Conjunctive Power†
ρ = 0
0.05
GSD graphic 0.094 0.722 0.082 (0.002+0.081)
GSMulti 0.063 0.718 0.046 (0+0.046)
GSMulti v 0.095 0.723 0.083 (0.001+0.082)
0.1
GSD graphic 0.270 0.734 0.231 (0.005+0.226)
GSMulti 0.208 0.718 0.152 (0.002+0.150)
GSMulti v 0.272 0.736 0.233 (0.003+0.230)
0.2
GSD graphic 0.784 0.781 0.642 (0.036+0.606)
GSMulti 0.722 0.718 0.517 (0.012+0.505)
GSMulti v 0.786 0.783 0.646 (0.024+0.622)
ρ = 0.25
0.05
GSD graphic 0.098 0.722 0.094 (0.004+0.090)
GSMulti 0.064 0.722 0.057 (0.001+0.055)
GSMulti v 0.099 0.725 0.094 (0.003+0.092)
0.1
GSD graphic 0.276 0.731 0.255 (0.011+0.244)
GSMulti 0.210 0.722 0.177 (0.004+0.173)
GSMulti v 0.278 0.734 0.257 (0.008+0.249)
0.2
GSD graphic 0.780 0.776 0.661 (0.057+0.605)
GSMulti 0.724 0.722 0.551 (0.023+0.528)
GSMulti v 0.782 0.779 0.665 (0.041+0.625)
ρ = 0.5
0.05
GSD graphic 0.101 0.721 0.100 (0.006+0.093)
GSMulti 0.067 0.730 0.065 (0.002+0.062)
GSMulti v 0.102 0.73 0.101 (0.004+0.097)
0.1
GSD graphic 0.283 0.727 0.275 (0.019+0.256)
GSMulti 0.218 0.730 0.202 (0.008+0.194)
GSMulti v 0.287 0.736 0.278 (0.014+0.265)
0.2
GSD graphic 0.775 0.772 0.686 (0.082+0.603)
GSMulti 0.730 0.730 0.594 (0.040+0.554)
GSMulti v 0.780 0.777 0.691 (0.061+0.629)
ρ = 0.75
0.05
GSD graphic 0.104 0.722 0.104 (0.010+0.094)
GSMulti 0.073 0.744 0.073 (0.004+0.069)
GSMulti v 0.105 0.744 0.105 (0.006+0.098)
0.1
GSD graphic 0.294 0.724 0.293 (0.029+0.264)
GSMulti 0.232 0.744 0.229 (0.014+0.215)
GSMulti v 0.298 0.746 0.296 (0.022+0.275)
0.2
GSD graphic 0.770 0.768 0.719 (0.111+0.607)
GSMulti 0.747 0.744 0.655 (0.065+0.590)
GSMulti v 0.783 0.780 0.727 (0.091+0.636)
*: pi1 = 0.0014;
†: Conjunctive power at the interim + Conjunctive power at the final;
GSMulti v: GSD with multivariate distribution using reallocating signifi-
cance level.
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3.4 Discussion
We have demonstrated a method using multivariate normal distribution for the group
sequential design with the two primary endpoints taking the correlation into the
consideration. In this design setting, the multiplicity issues from the repeated analyses
and from the multiple endpoints should be taken care of deliberately. We proposed a
procedure - GSD using multivariate normal distribution - to deal with the multiplicity
problems simultaneously. In practice, it is possible that the correlation can be
quantified or be estimated, therefore we derived the procedure under the assumption
of known correlation. The MVN distribution was applied to derive the stopping
boundaries numerically under the least favorable configuration with all effect sizes
as 0. The approach is a closed testing procedure and strongly control the familywise
error rate. The situation with unknown covariance matrix was considered for the
proposed method too. The inverse normal method was implemented and the original
stopping boundaries can be used directly when the variance is unknown. The stopping
boundaries could be updated based on the correlation observed in the interim analysis
and the FWER is shown to be controlled using the estimated correlation by simulation
study.
We conducted the extensive simulations to assess the performance of different
methods. T&G method is beneficial with the comparable effect sizes, but it is
disadvantageous when the effect sizes vary a lot. In general, the GSMulti method is an
alternative better way than T&G for the situations of the differential effect sizes, and
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it gains power of rejecting at least one endpoint substantially compared to the naive
Bonferroni GSD method with the strong correlation. Furthermore, the adjustment of
stopping boundaries for each endpoint is allowed in the GSMulti method based on
the clinical importance or the effect sizes. The unbalanced stopping boundaries have
shown to have higher power when the effect sizes of the primary endpoints differ. The
group sequential design with the multivariate distribution has the flexibility to stop
early to have lower average sample size compared to the fixed sample designs, with the
tradeoff as the increased maximum sample size in order to preserve the desired power.
As an extension of GSMulti method, we also discussed the reallocation of signifi-
cance level when the trial continues even if one endpoint is claimed efficiency in the
interim. As expected, the GSMulti with reallocation of significance level has higher
power than the standard GSMulti method due to the updated stopping boundaries.
This extension has promising applications in the studies, especially in the oncology
trials for the evaluation of different endpoints.
Although the situation with two primary endpoints was detailed elaborately in
this chapter, the proposed GSMulti can be generalized to more primary endpoints
with carefully derived stopping boundaries. For other types of endpoints, such as
binary and time-to-event endpoints, the further research needs to be done because
of the difficulty in the determination of correlation. Additionally, the GSMulti
approach can be employed in the group sequential designs with other inferential goal
settings. For example, the biomarker study, aiming at detecting the treatment effect
in the biomarker subpopulation or the overall population, has the joint test statistics
72
and the known correlation, in which the GSMulti method can be applied. Another
promising application is the multiple-arm group sequential design, where no adaptation
happens in the interim and the treatment is claimed as effective based on at least one
experimental group.
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Chapter 4
Flexible Drop-the-Loser Design
4.1 Introduction
A multiple arm trial, in which several treatment groups are compared with one control
group, has been widely studied. The main benefit of the multiple arm trial is the
fewer participants are recruited due to the shared control group in one single trial
compared to the separate multiple two-arm trials for different doses/treatments. In
general, comparing K treatment arms to a single control reduces the overall sample
size by a factor of (K − 1)/2K compared to K separate two arm trials (Freidlin et al.,
2008). Although the multiple arm trial has advantages of high efficiency of the drug
development and the lower administrative burden, the multiplicity issue from multiple
comparison testing is a challenge problem. The famlywise error rate is likely to be
higher than the significance level at which each comparison is tested if no multiplicity
adjustment is made. A powerful approach is described by Dunnett (Dunnett, 1955),
which takes the correlation among test statistics into consideration by the multivariate
normal distribution and could control familywise error rate in the strong sense.
However, traditional multiple arm design has a fixed sample size and does not
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allow the early termination of arms which show the futility or harm over the control
group. Multiple arm multiple stage (MAMS) trial, which has flexibility about stopping
decisions during the trial process, can help to improve the treatment evaluation over
fixed multiple arm design because the expected sample size and the length of time to
complete the trial will be reduced dramatically. Therefore, such design has gained a lot
of attentions. This type of design may be used in initial phases of drug development
to find appropriate dose, or in later phase trials in which multiple treatment options
are compared. One of the major difficulties implementing MAMS is the computational
cost with the increasing number of arms as well as the number of stages, and a lot of
special design structures were exploited to overcome this hurdle. Thall et al. (Thall
et al., 1988) introduced a two-stage multiple arm design which allows early stop for
futility in the interim analysis and only selects one best treatment to continue beyond
the first stage. A more flexible design was proposed (Schaid et al., 1990) in which
more arms can be carried to the final stage for the survival endpoints. Follmann et
al. (Follmann et al., 1994) extend the α-spending function to MAMS considering
dropping the treatments in the interim if they are significantly inferior to control.
Stallard and Todd (Stallard and Todd, 2003) generalized the work of Thall et al.
and Schaid et al. to various endpoints and to perform a number of interim analyses
comparing the selected and control treatments. Stallard and Friede (Stallard and
Friede, 2008) proposed a design which controls the FWER strongly if the number of
arms to be included in each stage is pre-specified. Magirr et al. (Magirr et al., 2012)
extended Dunnett test into multiple stage design in which the number of treatment
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arms in each stage does not need to be specified and they can be claimed based on the
efficacy or futility boundaries. Chang and Wang (Chang and Wang, 2015) developed
an add-arm design for unimodal response curve to drop or add arms based on the
efficacy or toxicity data. Wason et al. (Wason et al., 2017) studied MAMS designs by
maintaining a pre-specified schedule of dropping treatments, which is somewhat less
flexible than Stallard and Friede design, but it provided analytical formulae for the
exact operating characteristics.
Those existing literature research either needs to pre-specify the number of arms
to be dropped in each stage or only allows treatment selection based on efficacy. In
practice, more flexibility of treatment selection is necessary and the toxicity response
should be considered for dropping harmful arms sometimes. In this chapter, we study
a drop-the-loser design with the sufficient flexibility to consider the safety information
in the treatment selection without pre-specifying the dropping arms mechanism and
the designs still retain reasonable high power at the same. The assumption is the
independence between the efficacy data and the safety data. The two different types
of stopping boundaries are proposed for such a design. The sample size adjustment is
also allowed if the winner arm in the interim is dropped due to the safety concern.
For now, the assumption is made that the trial does not stop in the interim analysis
due to the efficacy claim, but it can stop because of the safety concern or the lack of
efficacy.
The chapter evolves as follows. We begin with the introduction of two methods
used for the drop-the-loser design allowing flexibility of treatment selection, followed
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by the sample size adjustment mechanism. The treatment selection is also discussed
based on the utility function integrating both efficacy and toxicity data. The extensive
simulation studies are conducted to compare the proposed methods. The Discussion
section provides the suggestions on the application for the specific situations and
concludes this chapter with a short summary.
4.2 Drop-the-Loser Design with Dunnett Test
In certain settings, for example, the multiple arm design with normal endpoints, the
power could be improved by taking advantage of the joint distribution of the test
statistics. Dunnett (Dunnett, 1955) developed such a parametric procedure for the
multiple dose-control comparisons. Consider the same design as in Section 1.1, the
test statistic for Dunnett test is:
T = max
k
tk. (4.1)
The multivariate t-distribution of T in Eq (4.1) is one-sided Dunnett distribution with
degree of freedom of ν = (K+1)(n−1). The Dunnett critical value, α1,K = F−1(1−α),
is evaluated under the global null hypothesis, where F (x) is the CDF of Dunnett
distribution:
F (x) = P (T ≤ x) =
∫ ∞
−∞
[Φ(t)]Kφ(
√
2x− t)dt.
The individual hypothesis Hk is rejected if tk ≥ α1,K , k = 1, . . . , K. The critical values
in p scale of one-sided Dunnett test for large sample size (degree of freedom) with test
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level α as 0.025 is shown in Table 4.1.
Table 4.1: Critical Values for comparing K treatment arms against
control group in one-sided Dunnett test.
Number of arms, K
1 2 3 4 5 6 7
α1,K 0.025 0.0135 0.0094 0.0073 0.0060 0.0051 0.0045
Test level α = 0.025.
The fixed sample size Dunnett test does not allow drop-the-loser, and the gener-
alized Dunnett test for MAMS design (Magirr et al., 2012) only makes the decision
based on the efficacy data in different stages. However, it is important that a study
has the flexibility to drop the arms based on other factors, such as safety profile, in
addition to the efficacy criterion. The intuitive and straightforward approach is to
apply Dunnett’s critical value directly in the final analysis of a MAMS design to test
any pairwise comparisons against the control group, allowing the arms dropped in the
interim analyses. The critical values α1,K are derived with the initial K treatment
arms using Dunnett distribution. This design is called the drop-the-loser design
using Dunnett test (DLDDunnett). The FWER of DLDDuneet is strongly controlled
because of the less or equal number of comparisons made in the final analysis and no
type I error rate happens to the dropped arms. This design deflates the error rate as:
α = sup Pr(Reject at least one Hk|H0) = sup Pr(∪Kk=1tk ≥ α1,K |H0)
≥ sup Pr(∪Lk=1tk ≥ α1,K |H0) = sup Pr(∪Lk=1tk ≥ α1,K |H0L), (4.2)
where L is the number of remaining arms in the final stage, H0L is the set of hypotheses
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for those remaining arms, which belongs to H0. The inequality is due to the removal
of some union sets. For other configurations of null hypothesis, it can show that the
error of testing remaining arms is smaller than the error of traditional Dunnett test in
the similar manner. Therefore, this design is a conservative approach but it provides
flexibility allowing for any number of interim analyses performed at any time, and
any number of arms dropped without pre-specifying criteria in advance. DLDDunnett
could also save sample size if some treatment arms are dropped in the interim stages
compared to the fixed sample size Dunnett test.
4.3 Drop-the-Loser Design with Gatekeeping Procedure
DLDDunnett uses the Dunnett-adjusted critical values based on the initial number
of arms and could be inefficient especially when large number of arms are dropped
before the final stage. We further propose a method extended from the traditional
two-stage pick-the-winner design (PWD) (Chang, 2014), called drop-the-loser design
with gatekeeping procedure (DLDGKP), to improve the efficiency of the design. The
traditional PWD starts with all doses, the winner selected in the interim analysis with
the best observed efficacy will continue to the second stage with the control group
and the rejection decision is only allowed in the final stage. The distribution of final
test statistic of PWD and the corresponding critical values were also derived (Chang,
2014). Table 4.2 shows the critical values ατ,K for the PWD given test level α as
0.025.
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Table 4.2: Critical Values ατ,K for the traditional pick-the-winner
design with K treatment arms.
Number of arms, K
Information time τ 1 2 3 4 5 6 7
0.5 0.025 0.0151 0.0114 0.0093 0.0080 0.0071 0.0064
0.7 0.025 0.0143 0.0104 0.0082 0.0069 0.0060 0.0054
1 0.025 0.0135 0.0094 0.0073 0.0060 0.0051 0.0045
Test level α = 0.025.
For the proposed DLDGKP, the arms could be dropped but no testing is conducted
in the interim analyses; at the final stage, the pairwise comparisons are tested in a
gatekeeping inference. Specifically, if the winner arm selected based on efficacy in the
interim analysis is dropped due to the safety problem or other criteria and it is not
included in the final analysis, the pairwise comparisons left in the final stage could
be conducted in any testing order using the Dunnett critical value for K − 1 arms,
α1,K−1. Here, α1,K−1 is also the critical value of the special case of traditional PWD
given K-1 treatment arms and treatment selection in the final analysis. However,
if the winner arm is not dropped and has the significant effect against the control
group in the final stage at the test level of ατmax,K , the rest pairwise comparisons
could be tested at ατmax,K as well without any pre-specified order; otherwise, no
arms can be claimed significant. Here, ατmax,K is the critical value of the traditional
two-stage PWD given K treatment arms and the information time of interim analysis
as τmax. The winner is picked in the last interim analysis performed no later than
information time of τmax. To control the FWER, the critical value of DLDGKP is
α∗τmax,K = min(ατmax,K , α1,K−1). Hence, the critical value for DLDGKP, α
∗
τmax,K
, is
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less stringent than the critical value for the Dunnett test, α1,K . In this way, DLDGKP
improves the design by sacrificing flexibility of interim analyses timing but still allows
for any number of analyses performed at any time before τmax to drop any number of
arms based on any criteria. The FWER of DLDGKP is also strongly controlled if the
treatment selection rule is positively correlated with the efficacy data. To show this,
we first prove the FWER control when the treatment selection rule is independent
from the efficacy data. Let D = 1 when the winner arm in the interim is dropped and
D = 0 otherwise; L be the number of remaining arms in the final stage; H0L be the
set of hypotheses for those remaining arms, which belongs to H0; pw be the p-value for
testing the interim selected winner arm versus control group in the final stage. Then,
sup Pr(Reject at least one Hk|H0L)
= sup Pr(D = 1 ∩ min
l∈{1,...,L}
(pl) ≤ α∗τmax,K |H0L) + sup Pr(D = 0 ∩ pw ≤ α∗τmax,K |H0L)
= sup Pr(D = 1) Pr( min
l∈{1,...,L}
(pl) ≤ α∗τmax,K |H0L) + sup Pr(D = 0) Pr(pw ≤ α∗τmax,K |H0L)
≤Pr(D = 1)α + Pr(D = 0)α = α,
where the inequality is because of
Pr( min
l∈{1,...,L}
(pl) ≤ α∗τmax,K |H0L) ≤ Pr( min
k∈{1,...,K−1}
(pk) ≤ α∗τmax,K |H0,(K−1)),
H0,(K−1) is the set of hypotheses for the arms excluding the interim selected winner
arm.
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Table 4.3 shows the critical value α∗τmax,K for different number of treatment groups
and the information time of last interim analysis. The optimal τmax could be chosen
so that α∗τmax,K = α1,K−1. Practically, the Dunnett test critical value α1,K−1 should
be used to find the largest information time τmax to drop the losers so that α
∗
τmax,K
=
ατ,K = α1,K−1. The optimal τmax with the corresponding α∗τmax,K is demonstrated in
Table 4.4.
Table 4.3: Critical Values α∗τmax,K for DLDGKP.
Number of arms, K
τmax 2 3 4 5 6 7
0.5 0.0151 0.0113 0.0093 0.0073 0.0060 0.0051
0.7 0.0143 0.0104 0.0082 0.0069 0.0060 0.0051
1 0.0135 0.0094 0.0073 0.0060 0.0051 0.0045
Overall test significance level α = 0.025.
Table 4.4: Optimal τmax with the corresponding critical Values α
∗
τmax,K
for DLDGKP.
Number of arms, K
3 4 5 6 7
τmax 0.285 0.492 0.625 0.715 0.775
α∗τmax,K 0.0135 0.0094 0.0073 0.0060 0.0051
Overall test significance level α = 0.025.
4.4 Drop-the-Loser Design with Adjustable Sample Size
In practice, the dose with higher efficacy usually has a higher toxicity rate. It is
unethical to keep highly toxic group in the trial and those groups should be dropped
even their efficacy data is significant. For the designs mentioned in Section 4.2 and 4.3,
when the winner arm indicated by the interim data is dropped due to the higher
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toxicity rate, the two designs can be modified allowing the sample size adjustment for
other remained arms to boost power. The critical values derived from DLDDunnett
and DLDGKP could be used for testing in the final stage as long as the arms dropped
and the sample size adjustment are independent of the observed effect sizes of arms.
4.5 Drop-the-Loser Design using Utility Function
One goal of a drop-the-loser design is to find the best dose/treatment in the interim for
the subsequent final test. Such a dose/treatment should have good efficacy performance
compared to the control group. However, the doses with superior efficacy tends to
have higher rates of adverse event, hence the safety issue should be taken into account
for the treatment selections. A utility function incorporating both efficacy and toxicity
data could be constructed to provide a balance between the two measurements, in
which, the doses/treatments with higher efficacy and lower toxicity rate have higher
values of utility function. The arm with maximum of the utility function will be
identified as the optimal treatment. A lot of utility functions were studied in the
literature for different combinations of efficacy and toxicity (Thall and Cook, 2004;
Ivanova et al., 2009; Dragalin and Fedorov, 2006; Fedorov et al., 2012).
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Here, we define the utility function as:
U = Ueff − Utox (4.3)
Ueff = (1 + 100exp(−βeff
δmin
x))−1
Utox = (1 + 100exp(− βtox
ζmax
x))−1,
where δmin is the minimum of clinical meaningful effect size, ζmax is the maximum
tolerated toxicity rate (MTTR), x is either the efficacy response or the toxicity rate
in the corresponding equation. βeff and βtox represent the gradients of utility curves
of efficacy and toxicity rate, respectively. β’s should be chosen so that the utility can
distinguish different values of efficacy or toxicity rate. In a DLD using utility function
criteria, the rules can be determined as:
• In the interim analyses, if the utility Uk,τ − U0,τ < 0.8Umin or Uk,τ < 0.5Umax, the
kth arm is dropped, where Umin is the minimum utility value required beyond the
control group, and Umax is the maximum observed utility value among all arms in the
interim analysis.
• In the final stage, two scenarios are used to test the effectiveness of arm without or
with concern of utility value:
1. The tests are performed for all the remaining arms no matter what the utility
is, and the power is defined as statistically significant in the hypothesis test for
at least one of those arms.
2. The tests are performed for the remaining arms with Uk,1 − U0,1 ≥ Umin, and
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the probability of success (PoS) is defined as statistically significant in the
hypothesis test for at least one of those arms with reasonable utility value in
the final stage. The reason for checking the PoS is to measure the quality of a
selected doses/treatments with larger sample size and enable the trials to have
doses/treatments that are highly effective but with the minimal side-effects.
The critical values in the final stage could be adopted using DLDDunnett introduced
above with the strong control of FWER as shown in the formula (4.2). DLDGKP can
also be implemented here with the FWER control demonstrated by the simulations in
Appendix J.
4.6 Simulation Study
4.6.1 Power Comparison between DLDDunnett and DLDGKP
First, we compare the drop-the-loser designs with Dunnett test and with gatekeeping
procedure using the extensive simulations. The two-stage DLDs with different number
of treatment arms and one control group are considered. Different response curves in
Table 4.5 are used for the normal efficacy endpoint and the binary toxicity endpoint.
Table 4.6 shows the optimal information time τmax for each number of treatment arms
with the incremental sample size in the first and second stage n1 and n2 listed as well.
In the simulation study, the arms are dropped in the interim if the observed toxicity
rate is larger than the maximum tolerated toxicity rate (MTTR) of 0.15. The average
sample size is then only dependent on the toxicity curve and shown in the last column
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of Table 4.6.
Table 4.7 shows the probability of claiming efficacy in each safe arm and the
overall disjunctive power of detecting at least one significant effect size in the safe
arms for the 4 treatment arms situation, and Figure 4·1 demonstrates only the overall
disjunctive power for the situations of 3 and 5 treatment arms. The scenario column
in Table 4.7 is for the different combination of efficacy and toxicity rate response
curves, in which the first one is for efficacy and the second is for toxicity rate. For
example, “Low-Low” stands for the low efficacy and low toxicity rate response curves.
The power for the high flat toxicity rate is close to 0 because the arms are dropped
due to the toxicity issues. From the simulation results, the disjunctive powers are
similar for DLDDunnett and DLDGKP in general. However, some dominant trends
could still be found. When the number of tested arms in the final stage is less than
the original number of arms due to safety issues, DLDGKP has higher power than
DLDDunnett because the later design wastes some alpha level on the dropped arms
therefore provides limited power. The power improvement by DLDGKP is larger if
more arms are dropped. For instance, the power of DLDGKP with four treatment
arms is 1.1% higher than that of DLDDunnett for Log-Linear scenario, while it is 2.6%
higher than DLDDunnett for Log-Log scenario because log toxicity curve tends to
drop more arms. In contrast, DLDGKP performs worse than DLDDunnett if all the
arms are carried to the end (“Low Flat” toxicity rate curve), which is reasonable since
it reduces to the standard multiple arm design and DLDGKP requires the winner arm
significant in the final stage.
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Table 4.5: Response curves of treatment groups for efficacy and toxicity
endpoints.
Scenario Three Treatment Arms1 2 3
Low Flat 0.1 0.1 0.1
High Flat 0.2 0.2 0.2
Linear 0.1 0.2 0.3
Four Treatment Arms
1 2 3 4
Low Flat 0.1 0.1 0.1 0.1
High Flat 0.2 0.2 0.2 0.2
Linear 0.05 0.1 0.15 0.2
Log-shape 0.1 0.2 0.25 0.25
Five Treatment Arms
1 2 3 4 5
Low Flat 0.1 0.1 0.1 0.1 0.1
High Flat 0.2 0.2 0.2 0.2 0.2
Linear 0.05 0.1 0.15 0.2 0.25
S-shape 0.05 0.05 0.2 0.25 0.25
Standardized normal efficacy endpoint and bi-
nary toxicity endpoint.
Table 4.6: Sample sizes used for different number of treatment arms.
Toxicity Optimal τmax n1 n2 AverageN
Three Treatment Arms
Low Flat
0.285 148 372
2055
High Flat 1042
Linear 1353
Four Treatment Arms
Low Flat
0.492 256 264
2595
High Flat 1566
Linear 2213
Log-shape 1813
Five Treatment Arms
Low Flat
0.625 325 195
3118
High Flat 2155
Linear 2633
S-shape 2637
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Table 4.7: Power comparisons between DLDDunnett and DLDGKP
with 4 treatment arms.
Scenario
Treatment arm k against control Overall
1 2 3 4 DisjunctivePower
DLDDunnett
Low-Low 0.202 0.202 0.201 0.200 0.448
Low-High 0.004 0.004 0.004 0.004 0.016
Low-Linear 0.203 0.202 0.104 0.004 0.357
Low-Log 0.202 0.004 0 0 0.205
High-Low 0.780 0.781 0.777 0.779 0.961
High-High 0.016 0.016 0.017 0.016 0.063
High-Linear 0.784 0.781 0.403 0.016 0.924
High-Log 0.780 0.016 0 0 0.782
Linear-Low 0.051 0.202 0.487 0.779 0.834
Linear-High 0.001 0.004 0.011 0.016 0.031
Linear-Linear 0.052 0.202 0.252 0.016 0.395
Linear-Log 0.051 0.004 0 0 0.055
Log-Low 0.202 0.781 0.937 0.938 0.988
Log-High 0.004 0.016 0.020 0.019 0.058
Log-Linear 0.203 0.781 0.487 0.019 0.884
Log-Log 0.202 0.016 0 0 0.215
DLDGKP
Low-Low 0.201 0.202 0.201 0.200 0.403
Low-High 0.005 0.005 0.005 0.004 0.018
Low-Linear 0.216 0.216 0.109 0.004 0.362
Low-Log 0.228 0.005 0 0 0.231
High-Low 0.790 0.791 0.788 0.788 0.931
High-High 0.017 0.017 0.017 0.016 0.065
High-Linear 0.802 0.799 0.412 0.016 0.920
High-Log 0.805 0.017 0 0 0.807
Linear-Low 0.061 0.223 0.504 0.751 0.792
Linear-High 0.001 0.005 0.011 0.016 0.033
Linear-Linear 0.061 0.226 0.265 0.016 0.420
Linear-Log 0.061 0.005 0 0 0.066
Log-Low 0.228 0.803 0.938 0.938 0.976
Log-High 0.005 0.017 0.020 0.020 0.060
Log-Linear 0.230 0.805 0.488 0.019 0.895
Log-Log 0.228 0.017 0 0 0.241
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Figure 4·1: Power comparisons between DLDDunnett and DLDGKP
for different number of treatment arms.
4.6.2 Adjustable Sample Size
In case that the most effective arm in the interim is dropped due to the high toxicity,
the sample size could increase to retain the targeted power. Here, the total sample size
will increase 50% if the winner selected by the observed efficacy data in the interim is
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dropped. In this way, the sample size adjustment does not depend on the effect size
of any arm, therefore the critical values proposed above could be applied directly. In
the simulation, the DLDGKP design with adjustable sample size (DLDGKP ASS) for
four treatment arms as in Section 4.6.1 is used. From the simulation results shown in
Table 4.8, the consideration of increasing sample size when the winner arm is dropped
in the interim helps to improve the power, especially for the uneven response curve
scenarios.
Table 4.8: Operating characteristics of DLDGKP without and with
adjustable sample size.
Scenario DLDGKP DLDGKP ASSPower AverageN Power AverageN
Low-Low 0.403 2595 0.403 2600
Low-High 0.018 1566 0.028 1837
Low-Linear 0.362 2213 0.427 2529
Low-Log 0.231 1813 0.340 2201
High-Low 0.931 2595 0.931 2600
High-High 0.065 1566 0.075 1837
High-Linear 0.920 2213 0.945 2529
High-Log 0.807 1813 0.910 2201
Linear-Low 0.792 2595 0.793 2600
Linear-High 0.033 1566 0.041 1837
Linear-Linear 0.420 2213 0.543 2891
Linear-Log 0.066 1813 0.116 2326
Log-Low 0.976 2594 0.976 2600
Log-High 0.060 1566 0.066 1838
Log-Linear 0.895 2213 0.949 2751
Log-Log 0.241 1813 0.379 2330
4.6.3 Utility Function
The simulations are also conducted to compare the efficiency of DLDDunnett and
DLDGKP when using the utility function introduced in Section 4.5. The efficacy and
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toxicity response curves for four treatment arms in Table 4.5 and the sample size with
optimal τmax in Table 4.6 are considered here. For the utility function in Eq. (4.3),
let the minimum effect size δmin be 0.15, the MTTR ζmax be 0.15, and βeff , βtox be 3.
The minimum utility value required beyond the control group Umin is set to 0.01. The
two different testing scenarios discussed in Section 4.5 is considered. Table 4.9 shows
the simulation results. The power of success is less than the power only dropping the
arms in the interim, which is intuitive since the more arms are likely to be dropped
in the early case. Generally, DLDGKP performs better than DLDDunnett when the
average sample size is small/the number of treatment arms left in the final stage is
small, which confirms the findings in Section 4.6.1 as well. In addition, compared
to Figure 4·1 only using safety data to drop arms, DLD with utility function can
still preserve high power by retaining the arms with high toxicity if the drug is very
efficacious. Hence, the employment of utility function helps to simultaneously examine
the efficacy and toxicity profile and make a balance between two.
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Table 4.9: Comparisons between DLDDunnett and DLDGKP using
utility function and traditional Pick-the-Winner designs.
Scenario
DLD PWD
DLDGKP DLDDunnett AverageN Power AverageNPower PoS Power PoS
Low-Low 0.385 0.371 0.377 0.365 1851
0.403 1808Low-High 0.135 0.032 0.127 0.032 1605
Low-Linear 0.352 0.316 0.330 0.298 1815
Low-Log 0.204 0.159 0.186 0.146 1675
High-Low 0.931 0.931 0.949 0.949 2109
0.932 1808High-High 0.867 0.762 0.865 0.764 1900
High-Linear 0.930 0.928 0.937 0.934 2044
High-Log 0.883 0.832 0.870 0.820 1887
Linear-Low 0.787 0.785 0.796 0.795 1905
0.793 1808Linear-High 0.538 0.385 0.529 0.384 1722
Linear-Linear 0.639 0.561 0.621 0.548 1848
Linear-Log 0.293 0.124 0.285 0.121 1666
Log-Low 0.976 0.976 0.985 0.985 2086
0.976 1808Log-High 0.946 0.915 0.948 0.918 1936
Log-Linear 0.970 0.969 0.972 0.971 2042
Log-Log 0.843 0.722 0.836 0.717 1885
4.7 Discussion
Multiple arm multiple stage design gains a lot of popularity due to the reduce of study
burden in term of the time and budget. Although various settings for MAMS design
were proposed with different treatment selection rules, none of them have flexibility of
dropping or selecting arms without pre-specified criteria but also incorporate other
factors such as safety issues. In this chapter, the traditional fixed sample size Dunnett
test was firstly extended to the drop-the-loser design, which allows any number
of interim analyses performed at any time to drop any number of arms based on
any criteria. This design can save sample size if some doses/treatments drop in
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the interim and provide large decision space for the investigators who do not have
too much information about efficacy and/or safety in the beginning and prefer to
conduct the design without pre-determined rules. Another type of DLD based on
the traditional pick-the-winner design was constructed to test the treatment arms
in the gatekeeping procedure (DLDGKP) in the final stage. DLDGKP sacrifices
some unnecessary flexibility of any interim time for performing dropping arms, and it
requires dropping arms in the optimal interim time for the higher power. Through the
extensive simulation using different dropping arms rules for different combination of
response curves, the power of the proposed two designs: DLDDunnett and DLDGKP, is
compared thoroughly. The performance of two designs are quite similar, but DLDGKP
has advantage when the number of arms left in the final testing stage is small compared
to the initial number of arms.
To further improve the performance of DLDGKP, the sample size adjustment is
allowed when the winner arm selected in the interim is dropped due to the other
factors, except efficacy data, such as high toxicity rate. The sample size could increase
in such situation to improve the power of detecting treatment effects. The traditional
test statistics could be used and the critical values proposed in the chapter can be
applied directly with the control of the FWER.
In practice, the utility function is usually discussed to offer a balanced measure
between efficacy and toxicity. We defined a utility function based on efficacy and
toxicity rate and integrated the utility function into the drop-the-loser design. The
rules of dropping arms based on the utility function are specified in a way that the
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arms with the reasonable utility are kept for the final test, and two different types of
power were considered: the power of claiming significance among the arms retained in
the interim, and the power of of claiming significance among the successful arms in
the final stage. However, the utility function is subjective and the criteria used for
treatment selection would vary a lot according to different drugs and study designs.
The implementation of utility function requires the understanding of the treatment
characteristics and should be carefully considered and constructed for each study drug.
The assumption of the proposed designs about the independence between efficacy
and safety might not be satisfied in practice. The correlated case should be studied in
the future as well. It is also desired sometimes that the trial can be designed so that
it allows early stopping for efficacy or futility, although it might lose some flexibilities
of treatment selection. In such situations, the proposed designs cannot be directly
applied. The further investigation of including the early stopping is needed to be
done. In practice, phase II clinical trials might use a rapidly observable short term
response in order to accelerate the drug development, which is different from the
primary endpoint that the Phase III evaluation is based on. The incorporation of
these aspects into the selection designs proposed is the subject of continuing research.
94
Chapter 5
Summary and Discussion
In this dissertation, we worked on three different topics about multiple testing problems
in the classical clinical trial and adaptive designs. We proposed three novel approaches
for different designs and showed the advantage of taking the correlation into account
when conducting the multiple testing procedure.
In the first topic, we built a novel and efficient single-step progressive parametric
multiple (SPPM) testing procedure for the normal distributed data allowing for the
consideration of correlation among the test statistics for the individual hypotheses,
which constructs the testing by limiting the upper bounds of products of local p-values.
SPPM controls the FWER in the strong sense because it is based on closure principle.
The critical values could be obtained by the numerical integration for the low dimension
of hypotheses (K = 2, or 3), or by the simulation for the high dimension of hypotheses
(K > 4). We studied the power performance of SPPM in comparison with other
multiple testing procedures and suggested the situations that SPPM provides higher
power. However, the implementation of SPPM in other type of data (such as binary
data or time-to-event data), and application in the unequal pairwise correlation for
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large number of hypotheses are required further research. Since SPPM allows the
alpha splitting among different hypotheses testing, the optimal way to split alpha in
order to get the highest power is still a question mark for the future study.
In the second topic, we developed a method via multivariate normal distribution
for a two-stage group sequential design with two primary endpoints (GSMulti), which
simultaneously considers the correlation between primary endpoints and between
repeated looks. The approach is a closed testing procedure as well and thus strongly
controls the FWER. Since the correlation is always a concern for the investigators
when conducting a clinical trial, we suggested to use the observed correlation based
on the first stage data and update the stopping boundary according to the estimated
correlation. In addition, the reallocation of significance level was also discussed when
the trial needs to continue even if one endpoint is claimed efficiency in the interim.
The same difficulty as in the first topic about definition of correlation exists for the
GSMulti method and extension to the binary or survival endpoint would require more
work.
The main assumption for the first two topics is the normal distributed data as
mentioned above. It is also straightfoward to apply the proposed methods when the
correlation among the normal test statistics is known or could be estimated. For
the unknown distribution of test statistics, the further studies are required. Here,
we discussed the application in the tests for K samples with survival outcome. To
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compare the hazard rates of K samples, the hypothesis of interest is:
H0 : h1(t) = h2(t) = . . . = hK(t), for all t ≤ τ,
Ha : at least one of hj(t)’s is different for some t ≤ τ,
where τ is the largest time at which all the groups have at least one subject at
risk. Assume t1 < t2 < . . . < tD be the distinct death times in the pooled sample,
and we observe dij events and Yij subjects at risk at time ti in the j
th sample, with
j = 1, . . . , K and i = 1, . . . , D. Let di =
∑K
j=1 dij be the number of deaths and
Yi =
∑K
i=1 Yij be the number of subjects at risk in the pooled sample at time ti. Then,
the test statistic is: Zj(τ) =
∑D
i=1 Wj(ti)(
dij
Yij
− di
Yi
), j = 1, . . . , K, where Wj(ti) is the
weight function and Wj(ti) = YijW (ti) is used in practice. The variance of Zj(τ) is:
σˆjj =
D∑
i=1
W (ti)
2Yij
Yi
(1− Yij
Yi
)(
Yi − di
Yi − 1 ), j = 1, . . . , K,
and the covariance of Zj(τ) and Zg(τ) is given by:
σˆjg = −
D∑
i=1
W (ti)
2Yij
Yi
Yig
Yi
(
Yi − di
Yi − 1 ), j 6= g.
When the sample size is large enough, the joint distribution of Zj(τ) is asymptotic
multivariate normal distribution and the proposed SPPM or GSMulti could be imple-
mented to test multiple groups with survival outcome. However, the multiple survival
endpoints, for example, progress-free survival and overall survival, need the definition
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of correlation among test statistics before utilizing our procedures.
In the third topic, we discussed the drawbacks of the existing methods for multiple
arm multiple stage (MAMS) design and developed two different approaches offering
more flexibilities. We first applied the traditional Dunnett test in the drop-the-loser
(DLDDunnett) design, which allows any number of interim analyses performed at any
time to drop any number of arms based on any criteria. The Dunnett critical value
based on the initial number of arms is used in the final stage to test the left arms.
Based on that, we developed a DLD in gatekeeping testing procedure (DLDGKP)
depending on the remaining of the winner arm selected in the interim, with the
treatment selection prior the pre-specified information time. Although DLDGKP is
less flexible, it provides higher power when the number of arms remaining in the final
stage is pretty small compared to the initial number of arms. Furthermore, we also
demonstrated the sample size adjustment when the winner arm selected in the interim
is dropped, and the treatment selection based on the utility function balancing the
efficacy and toxicity data. In the future, we will extend these two approaches by
allowing the early stopping for the efficacy or the futility.
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Appendix A
FWER under the Global Null Hypothesis
To derive the critical values that can control the familywise error rate strongly, the
least favorable configuration of µ′ks is identified by the intensive simulations. Figure
A.1 shows the error rate by the means under two null hypotheses with different
correlations, from which the FWER is increasing in two means and the maximum
value is achieved when two µ′ks are maximized under the global null (µ1 = µ2 = 0).
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Figure A·1: FWER under the global null hypothesis with the different
correlations.
Appendix B
R function for Critical values of
Two-Hypothesis Testing
library(mnormt)
twohypo_func <-function(rho ,alpha ,ratio){ ##rho is the
correlation , alpha is the test level and ratio is for
the allocation of critical values
s1<-matrix(c(1,rho ,rho ,1) ,2,2)
Fxy <-sadmvn(lower=c(qnorm(1-alpha),qnorm(1-alpha)),upper=c
(Inf ,Inf),c(0,0),s1)
solve_boundary1 <-function(alpha1){
integrand1 <-function(p1) pnorm (( qnorm(1-alpha1/p1)-rho*
qnorm(1-p1))/sqrt(1-rho^2),lower.tail=T)
t<-alpha -Fxy[1]- integrate(integrand1 ,lower=alpha1 ,upper=
alpha)$value
return(t)}
solve_boundary2 <-function(alpha1){
integrand1 <-function(p1) pnorm (( qnorm(1-alpha1/p1)-rho*
qnorm(1-p1))/sqrt(1-rho^2),lower.tail=T)
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integrand2 <-function(p2) pnorm (( qnorm(1-alpha1*ratio/p2)-
rho*qnorm(1-p2))/sqrt(1-rho^2),lower.tail=T)
t<-alpha -Fxy[1]- integrate(integrand1 ,lower=alpha1 ,upper=
alpha)$value -integrate(integrand2 ,lower=alpha1*ratio ,
upper=alpha)$value
return(t)}
solve_boundary3 <-function(alpha1){
integrand1 <-function(p1) pnorm (( qnorm(1-alpha1/p1)-rho*
qnorm(1-p1))/sqrt(1-rho^2),lower.tail=T)
integrand2 <-function(p1) pnorm (( qnorm(1-alpha)-rho*qnorm
(1-p1))/sqrt(1-rho ^2),lower.tail=T)
t<-integrate(integrand1 ,lower=alpha1/alpha ,upper=alpha)$
value -integrate(integrand1 ,lower=alpha1 ,upper=alpha)$
value+integrate(integrand2 ,lower=0,upper=alpha1/alpha)$
value
return(t)}
solve_boundary4 <-function(alpha1){
integrand1 <-function(p1) pnorm (( qnorm(1-alpha1/p1)-rho*
qnorm(1-p1))/sqrt(1-rho^2),lower.tail=T)
integrand2 <-function(p2) pnorm (( qnorm(1-alpha1*ratio/p2)-
rho*qnorm(1-p2))/sqrt(1-rho^2),lower.tail=T)
integrand3 <-function(p1) pnorm (( qnorm(1-alpha)-rho*qnorm
(1-p1))/sqrt(1-rho ^2),lower.tail=T)
t<-integrate(integrand1 ,lower=alpha1/alpha ,upper=alpha)$
value -integrate(integrand1 ,lower=alpha1 ,upper=alpha)$
value -integrate(integrand2 ,lower=alpha1*ratio ,upper=
alpha)$value+integrate(integrand3 ,lower=0,upper=alpha1/
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alpha)$value
return(t)}
##Nested search for stopping boudnary
if (class(try(uniroot(solve_boundary1 ,c(alpha^2,alpha))))!
="try -error") {alpha1 <-uniroot(solve_boundary1 ,c(alpha
^2,alpha),tol=1e-06)} else if (class(try(uniroot(solve_
boundary2 ,c(alpha^2,alpha/ratio))))!="try -error") {
alpha1 <-uniroot(solve_boundary2 ,c(alpha^2,alpha/ratio),
tol=1e-06)} else if (class(try(uniroot(solve_boundary3 ,
c(0.00001 , alpha ^2))))!="try -error") {alpha1 <-uniroot(
solve_boundary3 ,c(0.00001 , alpha ^2),tol=1e-06)} else if
(class(try(uniroot(solve_boundary4 ,c(0.00001 , alpha ^2)))
)!="try -error") {alpha1 <-uniroot(solve_boundary4 ,c
(0.00001 , alpha ^2),tol=1e-06)}
return(alpha1$root)
}
##Example: to obtain the equal critical values given rho
=0.5 and alpha=0.025, need to call the function:
twohypo_func(rho=0.5, alpha =0.025 , ratio =1)
[1] 0.001823292
Appendix C
Critical values for Three-Hypothesis
Testing
In the three-hypothesis testing, Eq. (9) shows the probability of type I error under
each hypothesis. With the proposed SPPM procedure,
P1 = sup
µ1∈H1
Pr(Reject H1|H1)
= sup
µ1∈H1
Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p1p3 ≤ α1 ∩ p1 ≤ α0|H1)
= sup
µ1∈H1
Pr(p1 ≤ α0|H1) = α;
P12 = sup
µ1,µ2∈H1∩H2
Pr(Reject either H1 or H2|H1 ∩H2)
= sup
µ1,µ2∈H1∩H2
Pr((p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p1p3 ≤ α1 ∩ p1 ≤ α0|H1 ∩H2)
∪ (p1p2p3 ≤ α4 ∩ p1p2 ≤ α2 ∩ p2p3 ≤ α2 ∩ p2 ≤ α0|H1 ∩H2))
= sup
µ1,µ2∈H1∩H2
Pr((p1p2 ≤ α1 ∩ p1 ≤ α0) ∪ (p1p2 ≤ α2 ∩ p2 ≤ α0)|H1 ∩H2) = α,
where α0 = α and P12 has the same formula as the error rate of two-hypothesis and
α1 and α2 can be derived correspondingly. The error rates under other hypothesis
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consisting of one or two individual hypotheses can be shown in the same way. Then,
P0 = sup
µ′is∈H0
Pr(Reject at least one Hi|H0) (C.1)
= Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p1p3 ≤ α1 ∩ p1 ≤ α)
+ Pr(p1p2p3 ≤ α4 ∩ p2p1 ≤ α2 ∩ p2p3 ≤ α2 ∩ p2 ≤ α)
+ Pr(p1p2p3 ≤ α4 ∩ p3p1 ≤ α3 ∩ p3p2 ≤ α3 ∩ p3 ≤ α)
− Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p1p3 ≤ α1 ∩ p2p3 ≤ α2 ∩ p1 ≤ α ∩ p2 ≤ α)
− Pr(p1p2p3 ≤ α4 ∩ p2p1 ≤ α2 ∩ p2p3 ≤ α2 ∩ p1p3 ≤ α3 ∩ p2 ≤ α ∩ p3 ≤ α)
− Pr(p1p2p3 ≤ α4 ∩ p1p3 ≤ α3 ∩ p2p3 ≤ α3 ∩ p1p2 ≤ α1 ∩ p3 ≤ α ∩ p1 ≤ α)
+ Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p1p3 ≤ α1 ∩ p2p3 ≤ α2 ∩ p1 ≤ α ∩ p2 ≤ α ∩ p3 ≤ α)
:= pi1 + pi2 + pi3 − pi12 − pi23 − pi31 + pi123,
whose formulation again requires the joint distribution of test statistics on p-value
scale and the conditional distribution. The joint distribution of test statistics for 3
hypotheses follows multivariate distribution: (
Z1
Z2
Z3
) ∼ MVN3((
µ1
µ2
µ3
),Σ). According to
the property of the conditional MNV, the distribution of Z3, given that Z1 = z1 and
Z2 = z2, is:
Z3|z1, z2 ∼ N(µ3 + ρ
1 + ρ
(z1 − µ1 + z2 − µ2), 1− 2ρ
2
1 + ρ
). (C.2)
It is easy to show that Eq. (C.1) achieves maximum value when all µ′ks equal to 0
under the global null. Then, the joint distribution of test statistics on p-value scale
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can be derived by incorporating the Jacobian of the transformation, which is:
f(p1, p2) =
exp{− 1
2(1−ρ2)(Φ
−1(1− p1)2 + Φ−1(1− p2)2 − 2ρΦ−1(1− p1)Φ−1(1− p2))}
2pi
√
1− ρ2φ(Φ−1(1− p1))φ(Φ−1(1− p2))
If α1 < α4, then the integral region to calculate pi
1
3 is in Figure C·1, and
pi13 = Pr(p3p1 ≤ α1 ∩ p3p2 ≤ α1 ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1
+ 2
∫∫
Ω2
Pr(p3 ≤ α1
p1
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·1: Integral region of pi13.
If
α21
α
< α4 ≤ α1, then the integral region to calculate pi23 is in Figure C·2, and
pi23 = Pr(p1p2p3 ≤ α4 ∩ p3p1 ≤ α1 ∩ p3p2 ≤ α1 ∩ p3 ≤ α))
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1
+ 2
∫∫
Ω3
Pr(p3 ≤ α1
p1
|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω2
Pr(p3 ≤ α4
p1p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·2: Integral region of pi23.
If α4 ≤ α
2
1
α
, then the integral region to calculate pi33 is in Figure C·3, and
pi33 = Pr(p1p2p3 ≤ α4 ∩ p3p1 ≤ α1 ∩ p3p2 ≤ α1 ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1
+ 2
∫∫
Ω3
Pr(p3 ≤ α1
p1
|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω2
Pr(p3 ≤ α4
p1p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·3: Integral region of pi33.
If α1α ≤ α4, then the integral region to calculate pi131 is in Figure C·4, and
pi131 = Pr(p1p2 ≤ α1 ∩ p3p2 ≤ α1 ∩ p1 ≤ α ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω2
Pr(p3 ≤ α1
p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·4: Integral region of pi131.
If α21 < α4 < α1α, then the integral region to calculate pi
2
31 is in Figure C·5, and
pi231 = Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p3p2 ≤ α1 ∩ p1 ≤ α ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω2
Pr(p3 ≤ α1
p2
|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω3
Pr(p3 ≤ α4
p1p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·5: Integral region of pi231.
If α4 ≤ α21, then the integral region to calculate pi331 is in Figure C·6, and
pi331 = Pr(p1p2p3 ≤ α4 ∩ p1p2 ≤ α1 ∩ p3p2 ≤ α1 ∩ p1 ≤ α ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1 +
∫∫
Ω2
Pr(p3 ≤ α1
p2
|p1, p2)f(p1, p2) dp2 dp1
+
∫∫
Ω3
Pr(p3 ≤ α4
p1p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·6: Integral region of pi331.
If α3 ≤ α4, then the integral region to calculate pi1123 is in Figure C·7, and
pi1123 = Pr(p1 ≤ α ∩ p2 ≤ α ∩ p3 ≤ α).
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Figure C·7: Integral region of pi1123.
If α4 < α
3, then the integral region to calculate pi2123 is in Figure C·8, and
pi2123 = Pr(p1p2p3 ≤ α4 ∩ p1 ≤ α ∩ p2 ≤ α ∩ p3 ≤ α)
=
∫∫
Ω1
Pr(p3 ≤ α|p1, p2)f(p1, p2) dp2 dp1 +
∫∫
Ω2
Pr(p3 ≤ α4
p1p2
|p1, p2)f(p1, p2) dp2 dp1
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Figure C·8: Integral region of pi2123.
In summary,
P0 =

3pi33 − 3pi331 + pi2123, α4 ≤ min(α21, α3);
3pi33 − 3pi231 + pi2123, min(α21, α3) < α4 ≤ max(α21, α3) ;
3pi33 − 3pi231 + pi1123, max(α21, α3) < α4 ≤ α1α;
3pi33 − 3pi131 + pi1123, α1α < α4 ≤
α21
α
;
3pi23 − 3pi131 + pi1123,
α21
α
< α4 ≤ α1;
3pi13 − 3pi131 + pi1123, α4 > α1.
(C.3)
Appendix D
R function for Critical values of
Three-Hypothesis Testing
threehypo_func <-function(alpha ,rho ,ratio){
alpha1 <-twohypo_func(rho=rho ,alpha=alpha ,ratio=ratio)
solve_boundary1 <-function(alpha4){
func1 <-function(p1,p2) (1-pnorm((qnorm(1-alpha)-rho/(1+
rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+rho))
))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho^2)*(qnorm(1-p1)
^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/dnorm(
qnorm(1-p1))/dnorm(qnorm(1-p2))
func2 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p1)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func22 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p2)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
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(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func3 <-function(p1,p2) (1-pnorm((qnorm(1-alpha4/p1/p2)-
rho/(1+rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/
(1+ rho))))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho ^2)*(
qnorm(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-
p2)))/dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
##Value of pi3_3
pi3_3<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 , lower=0,upper=alpha1/alpha ,p1=p1)
[[1]]) ,lower=0,upper=alpha4/alpha1)$val+integrate(
function(p1) sapply(p1,function(p1) integrate(func1 ,
lower=0,upper=alpha4/alpha/p1,p1=p1)[[1]]) ,lower=alpha4
/alpha1 ,upper=alpha1/alpha)$val)+2*integrate(function(
p1) sapply(p1,function(p1) integrate(func2 , lower=0,
upper=alpha4/alpha1 ,p1=p1)[[1]]) ,lower=alpha1/alpha ,
upper =1)$val+( integrate(function(p1) sapply(p1,function
(p1) integrate(func3 , lower=alpha4/alpha/p1,upper=1,p1=
p1)[[1]]) ,lower=alpha4/alpha1 ,upper=alpha1/alpha)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func3 , lower=alpha4/alpha1 ,upper=1,p1=p1)[[1]]) ,lower=
alpha1/alpha ,upper =1)$val)
##Value of pi31_3
pi31_3<-(integrate(function(p1) sapply(p1 ,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha4/alpha1)$val+integrate(function(p1
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) sapply(p1 ,function(p1) integrate(func1 ,lower=0,upper=
alpha4/alpha/p1 ,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=
alpha)$val)+integrate(function(p1) sapply(p1,function(
p1) integrate(func22 ,lower=alpha1/alpha ,upper=1,p1=p1)
[[1]]) ,lower=0,upper=alpha4/alpha1)$val+( integrate(
function(p1) sapply(p1,function(p1) integrate(func3 ,
lower=alpha1/alpha ,upper=1,p1=p1)[[1]]) ,lower=alpha4/
alpha1 ,upper=alpha1)$val+integrate(function(p1) sapply(
p1 ,function(p1) integrate(func3 ,lower=alpha1/alpha ,
upper=alpha1/p1,p1=p1)[[1]]) ,lower=alpha1 ,upper=alpha)$
val+integrate(function(p1) sapply(p1,function(p1)
integrate(func3 ,lower=alpha4/alpha/p1,upper=alpha1/
alpha ,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=alpha)$val
)
##value of pi123_2
pi123_2<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 ,lower=0,upper=alpha ,p1=p1)[[1]]) ,lower
=0,upper=alpha4/alpha ^2)$val+integrate(function(p1)
sapply(p1,function(p1) integrate(func1 ,lower=0,upper=
alpha4/alpha/p1 ,p1=p1)[[1]]) ,lower=alpha4/alpha^2,upper
=alpha)$val)+integrate(function(p1) sapply(p1,function(
p1) integrate(func3 ,lower=alpha4/alpha/p1 ,upper=alpha ,
p1=p1)[[1]]) ,lower=alpha4/alpha^2,upper=alpha)$val
t<-3*pi3_3-3*pi31_3+pi123_2-alpha
return(t)}
solve_boundary2 <-function(alpha4){
func1 <-function(p1,p2) (1-pnorm((qnorm(1-alpha)-rho/(1+
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rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+rho))
))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho^2)*(qnorm(1-p1)
^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/dnorm(
qnorm(1-p1))/dnorm(qnorm(1-p2))
func2 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p1)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func22 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p2)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func3 <-function(p1,p2) (1-pnorm((qnorm(1-alpha4/p1/p2)-
rho/(1+rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/
(1+ rho))))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho ^2)*(
qnorm(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-
p2)))/dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
##Value of pi3_3
pi3_3<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 , lower=0,upper=alpha1/alpha ,p1=p1)
[[1]]) ,lower=0,upper=alpha4/alpha1)$val+integrate(
function(p1) sapply(p1,function(p1) integrate(func1 ,
lower=0,upper=alpha4/alpha/p1,p1=p1)[[1]]) ,lower=alpha4
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/alpha1 ,upper=alpha1/alpha)$val)+2*integrate(function(
p1) sapply(p1,function(p1) integrate(func2 , lower=0,
upper=alpha4/alpha1 ,p1=p1)[[1]]) ,lower=alpha1/alpha ,
upper =1)$val+( integrate(function(p1) sapply(p1,function
(p1) integrate(func3 , lower=alpha4/alpha/p1,upper=1,p1=
p1)[[1]]) ,lower=alpha4/alpha1 ,upper=alpha1/alpha)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func3 , lower=alpha4/alpha1 ,upper=1,p1=p1)[[1]]) ,lower=
alpha1/alpha ,upper =1)$val)
##Value of pi31_2
pi31_2<-(integrate(function(p1) sapply(p1 ,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha4/alpha1)$val+integrate(function(p1
) sapply(p1 ,function(p1) integrate(func1 ,lower=0,upper=
alpha4/alpha/p1 ,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=
alpha)$val)+( integrate(function(p1) sapply(p1,function(
p1) integrate(func22 ,lower=alpha1/alpha ,upper=1,p1=p1)
[[1]]) ,lower=0,upper=alpha1)$val+integrate(function(p1)
sapply(p1,function(p1) integrate(func22 ,lower=alpha1/
alpha ,upper=alpha1/p1,p1=p1)[[1]]) ,lower=alpha1 ,upper=
alpha4/alpha1)$val)+integrate(function(p1) sapply(p1,
function(p1) integrate(func3 ,lower=alpha4/alpha/p1 ,
upper=alpha1/p1,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=
alpha)$val
##value of pi123_2
pi123_2<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 ,lower=0,upper=alpha ,p1=p1)[[1]]) ,lower
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=0,upper=alpha4/alpha ^2)$val+integrate(function(p1)
sapply(p1,function(p1) integrate(func1 ,lower=0,upper=
alpha4/alpha/p1 ,p1=p1)[[1]]) ,lower=alpha4/alpha^2,upper
=alpha)$val)+integrate(function(p1) sapply(p1,function(
p1) integrate(func3 ,lower=alpha4/alpha/p1 ,upper=alpha ,
p1=p1)[[1]]) ,lower=alpha4/alpha^2,upper=alpha)$val
t<-3*pi3_3-3*pi31_2+pi123_2-alpha
return(t)}
solve_boundary3 <-function(alpha4){
func1 <-function(p1,p2) (1-pnorm((qnorm(1-alpha)-rho/(1+
rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+rho))
))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho^2)*(qnorm(1-p1)
^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/dnorm(
qnorm(1-p1))/dnorm(qnorm(1-p2))
func2 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p1)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func22 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p2)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func3 <-function(p1,p2) (1-pnorm((qnorm(1-alpha4/p1/p2)-
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rho/(1+rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/
(1+ rho))))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho ^2)*(
qnorm(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-
p2)))/dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
##Value of pi3_3
pi3_3<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 , lower=0,upper=alpha1/alpha ,p1=p1)
[[1]]) ,lower=0,upper=alpha4/alpha1)$val+integrate(
function(p1) sapply(p1,function(p1) integrate(func1 ,
lower=0,upper=alpha4/alpha/p1,p1=p1)[[1]]) ,lower=alpha4
/alpha1 ,upper=alpha1/alpha)$val)+2*integrate(function(
p1) sapply(p1,function(p1) integrate(func2 , lower=0,
upper=alpha4/alpha1 ,p1=p1)[[1]]) ,lower=alpha1/alpha ,
upper =1)$val+( integrate(function(p1) sapply(p1,function
(p1) integrate(func3 , lower=alpha4/alpha/p1,upper=1,p1=
p1)[[1]]) ,lower=alpha4/alpha1 ,upper=alpha1/alpha)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func3 , lower=alpha4/alpha1 ,upper=1,p1=p1)[[1]]) ,lower=
alpha1/alpha ,upper =1)$val)
##Value of pi31_2
pi31_2<-(integrate(function(p1) sapply(p1 ,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha4/alpha1)$val+integrate(function(p1
) sapply(p1 ,function(p1) integrate(func1 ,lower=0,upper=
alpha4/alpha/p1 ,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=
alpha)$val)+( integrate(function(p1) sapply(p1,function(
p1) integrate(func22 ,lower=alpha1/alpha ,upper=1,p1=p1)
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[[1]]) ,lower=0,upper=alpha1)$val+integrate(function(p1)
sapply(p1,function(p1) integrate(func22 ,lower=alpha1/
alpha ,upper=alpha1/p1,p1=p1)[[1]]) ,lower=alpha1 ,upper=
alpha4/alpha1)$val)+integrate(function(p1) sapply(p1,
function(p1) integrate(func3 ,lower=alpha4/alpha/p1 ,
upper=alpha1/p1,p1=p1)[[1]]) ,lower=alpha4/alpha1 ,upper=
alpha)$val
##value of pi123_1
s1<-matrix(c(1,rho ,rho ,rho ,1,rho ,rho ,rho ,1) ,3,3)
pi123_1<-sadmvn(lower=c(qnorm(1-alpha),qnorm(1-alpha),
qnorm(1-alpha)),upper=c(Inf ,Inf ,Inf),c(0,0,0),s1)[1]
t<-3*pi3_3-3*pi31_2+pi123_1-alpha
return(t)}
solve_boundary4 <-function(alpha4){
func1 <-function(p1,p2) (1-pnorm((qnorm(1-alpha)-rho/(1+
rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+rho))
))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho^2)*(qnorm(1-p1)
^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/dnorm(
qnorm(1-p1))/dnorm(qnorm(1-p2))
func2 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p1)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
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func22 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p2)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func3 <-function(p1,p2) (1-pnorm((qnorm(1-alpha4/p1/p2)-
rho/(1+rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/
(1+ rho))))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho ^2)*(
qnorm(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-
p2)))/dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
##Value of pi3_3
pi3_3<-(integrate(function(p1) sapply(p1,function(p1)
integrate(func1 , lower=0,upper=alpha1/alpha ,p1=p1)
[[1]]) ,lower=0,upper=alpha4/alpha1)$val+integrate(
function(p1) sapply(p1,function(p1) integrate(func1 ,
lower=0,upper=alpha4/alpha/p1,p1=p1)[[1]]) ,lower=alpha4
/alpha1 ,upper=alpha1/alpha)$val)+2*integrate(function(
p1) sapply(p1,function(p1) integrate(func2 , lower=0,
upper=alpha4/alpha1 ,p1=p1)[[1]]) ,lower=alpha1/alpha ,
upper =1)$val+( integrate(function(p1) sapply(p1,function
(p1) integrate(func3 , lower=alpha4/alpha/p1,upper=1,p1=
p1)[[1]]) ,lower=alpha4/alpha1 ,upper=alpha1/alpha)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func3 , lower=alpha4/alpha1 ,upper=1,p1=p1)[[1]]) ,lower=
alpha1/alpha ,upper =1)$val)
##Value of pi31_1
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pi31_1<-integrate(function(p1) sapply(p1,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha)$val+( integrate(function(p1)
sapply(p1,function(p1) integrate(func22 ,lower=alpha1/
alpha ,upper=1,p1=p1)[[1]]) ,lower=0,upper=alpha1)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func22 ,lower=alpha1/alpha ,upper=alpha1/p1,p1=p1)[[1]])
,lower=alpha1 ,upper=alpha)$val)
##value of pi123_1
s1<-matrix(c(1,rho ,rho ,rho ,1,rho ,rho ,rho ,1) ,3,3)
pi123_1<-sadmvn(lower=c(qnorm(1-alpha),qnorm(1-alpha),
qnorm(1-alpha)),upper=c(Inf ,Inf ,Inf),c(0,0,0),s1)[1]
t<-3*pi3_3-3*pi31_1+pi123_1-alpha
return(t)}
solve_boundary5 <-function(alpha4){
func1 <-function(p1,p2) (1-pnorm((qnorm(1-alpha)-rho/(1+
rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+rho))
))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho^2)*(qnorm(1-p1)
^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/dnorm(
qnorm(1-p1))/dnorm(qnorm(1-p2))
func2 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p1)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
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func22 <-function(p1,p2) (1-pnorm((qnorm(1-alpha1/p2)-rho/
(1+ rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/(1+
rho))))*1/2/pi/sqrt(1-rho ^2)*exp(-1/2/(1-rho ^2)*(qnorm
(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-p2)))/
dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
func3 <-function(p1,p2) (1-pnorm((qnorm(1-alpha4/p1/p2)-
rho/(1+rho)*(qnorm(1-p1)+qnorm(1-p2)))/sqrt(1-2*rho^2/
(1+ rho))))*1/2/pi/sqrt(1-rho^2)*exp(-1/2/(1-rho ^2)*(
qnorm(1-p1)^2+ qnorm(1-p2)^2-2*rho*qnorm(1-p1)*qnorm(1-
p2)))/dnorm(qnorm(1-p1))/dnorm(qnorm(1-p2))
##value of pi3_2
pi11 <-integrate(function(p1) sapply(p1,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha1/alpha)$val
pi121 <-integrate(function(p1) sapply(p1 ,function(p1)
integrate(func2 ,lower=0,upper=p1 ,p1=p1)[[1]]) ,lower=
alpha1/alpha ,upper=alpha4/alpha1)$val
pi122 <-integrate(function(p1) sapply(p1 ,function(p1)
integrate(func2 ,lower=0,upper=alpha4/alpha1 ,p1=p1)
[[1]]) ,lower=alpha4/alpha1 ,upper =1)$val
pi12 <-pi121+pi122
pi13 <-integrate(function(p1) sapply(p1,function(p1)
integrate(func3 ,lower=alpha4/alpha1 ,upper=1,p1=p1)
[[1]]) ,lower=alpha4/alpha1 ,upper =1)$val
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pi3_2=pi11+2*pi12+pi13
##Value of pi31_1
pi31_1<-integrate(function(p1) sapply(p1,function(p1)
integrate(func1 ,lower=0,upper=alpha1/alpha ,p1=p1)[[1]])
,lower=0,upper=alpha)$val+( integrate(function(p1)
sapply(p1,function(p1) integrate(func22 ,lower=alpha1/
alpha ,upper=1,p1=p1)[[1]]) ,lower=0,upper=alpha1)$val+
integrate(function(p1) sapply(p1,function(p1) integrate
(func22 ,lower=alpha1/alpha ,upper=alpha1/p1,p1=p1)[[1]])
,lower=alpha1 ,upper=alpha)$val)
##value of pi123_1
s1<-matrix(c(1,rho ,rho ,rho ,1,rho ,rho ,rho ,1) ,3,3)
pi123_1<-sadmvn(lower=c(qnorm(1-alpha),qnorm(1-alpha),
qnorm(1-alpha)),upper=c(Inf ,Inf ,Inf),c(0,0,0),s1)[1]
t<-3*pi3_2-3*pi31_1+pi123_1-alpha
return(t)}
if (class(try(uniroot(solve_boundary1 ,c(0+0.000001 , min(
alpha1^2,alpha ^3) -0.000001)),silent=T))!="try -error"){
alpha4 <-uniroot(solve_boundary1 ,c(0+ 0.000001 , min(
alpha1^2,alpha ^3) -0.000001) ,tol=1e-06)$root} else if (
class(try(uniroot(solve_boundary2 ,c(min(alpha1^2,alpha
^3)+ 0.000001 , max(alpha1^2,alpha ^3) -0.000001)),silent=T
))!="try -error"){alpha4 <-uniroot(solve_boundary2 ,c(min(
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alpha1^2,alpha ^3)+ 0.000001 , max(alpha1^2,alpha ^3)
-0.000001)$root ,tol=1e-06)} else if (class(try(uniroot(
solve_boundary3 ,c(max(alpha1^2,alpha ^3)+ 0.000001 ,
alpha1*alpha -0.000001)),silent=T))!="try -error"){alpha4
<-uniroot(solve_boundary3 ,c(max(alpha1^2,alpha ^3)+
0.000001 , alpha1*alpha -0.000001) ,tol=1e-06)$root} else
if (class(try(uniroot(solve_boundary4 ,c(alpha1*alpha+
0.000001 , alpha1 ^2/alpha -0.000001)),silent=T))!="try -
error"){alpha4 <-uniroot(solve_boundary4 ,c(alpha1*alpha+
0.000001 , alpha1 ^2/alpha -0.000001) ,tol=1e-06)$root}
else if (class(try(uniroot(solve_boundary5 ,c(alpha1 ^2/
alpha+ 0.000001 , alpha1 -0.000001)),silent=T))!="try -
error"){alpha4 <-uniroot(solve_boundary5 ,c(alpha1 ^2/
alpha+ 0.000001 , alpha1 -0.000001) ,tol=1e-06)$root}else {
alpha4 <-1}
return(c(alpha1 ,alpha4))
}
##Example: to obtain the critical values given rho=0.5 and
alpha=0.025, need to call the function:
threehypo_func(alpha =0.025 , rho=0.5, ratio =1)
[1] 0.001823292 0.001079318
##0.001823 is for alpha_1 and 0.00108 is for alpha_4.
Appendix E
Strong Control of FWER for SPPM
testing procedure
To verify the FWER control of the proposed SPPM testing procedure, we conducted
simulations under two- and three- hypothesis testing frameworks.
Table E.1: Familywise error rate for two-hypothesis testing using
SPPM given α = 0.025.
Correlation µ1 = µ2 = 0 µ1 = 0, µ2 = 0.01 µ1 = 0, µ2 = 0.3
ρ = −0.99 0.0250 0.0126 0.0249
ρ = −0.5 0.0257 0.0129 0.0246
ρ = 0 0.0250 0.0132 0.0246
ρ = 0.5 0.0253 0.0155 0.0249
ρ = 0.99 0.0247 0.0242 0.0249
Table E.2: Familywise error rate for three-hypothesis testing using
SPPM given α = 0.025.
Correlation µ1 = µ2 µ1 = µ2 = 0 µ1 = µ2 = 0 µ1 = 0= µ3 = 0 µ3 = 0.01 µ3 = 0.3 µ2 = µ3 = 0.3
ρ = −0.5 0.0251 0.0174 0.0249 0.0247
ρ = 0 0.0259 0.0181 0.0254 0.0248
ρ = 0.5 0.0256 0.0203 0.0256 0.0251
ρ = 0.99 0.0249 0.0249 0.0252 0.0252
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Appendix F
FWER in Two-Hypothesis Testing using
Estimated Covariance Matrix
The FWERs under different configurations of null hypotheses in the two-hypothesis
testing were also evaluated via simulation to show the strong control of SPPM testing
procedure using the estimated covariance matrix. The results are shown in Table F.1.
Table F.1: Familywise error rate using SPPM procedure with the
estimated covariance for two-hypothesis testing given α = 0.025 (100,000
simulations).
N = 15 N = 60 N = 120 N = 500 N = 1000
µ1 = 0, µ2 = 0.3
ρ = −0.99 0.0256 0.0276 0.0258 0.0254 0.0248
ρ = −0.5 0.0286 0.0267 0.0257 0.0254 0.0248
ρ = 0 0.0297 0.0270 0.0257 0.0254 0.0248
ρ = 0.5 0.0326 0.0275 0.0257 0.0254 0.0248
ρ = 0.99 0.0357 0.0276 0.0258 0.0254 0.0248
µ1 = −0.3, µ2 = 0.3
ρ = −0.99 0.0009 0 0 0 0
ρ = −0.5 0.0012 1e-05 0 0 0
ρ = 0 0.0015 1e-05 0 0 0
ρ = 0.5 0.0018 1e-05 0 0 0
ρ = 0.99 0.0019 1e-05 0 0 0
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Appendix G
R function for the stopping boundaries
calculation
library(mnormt)
c_values <-function(interim ,rho ,alpha1 ,alpha ,ratio){
s1<-matrix(c(1,rho ,rho ,1) ,2,2) ##covariance matrix for
the 1st stage test statistics
s2<-matrix(c(1,rho ,sqrt(interim),sqrt(interim)*rho ,rho ,1,
sqrt(interim)*rho ,sqrt(interim),sqrt(interim),sqrt(
interim)*rho ,1,rho ,sqrt(interim)*rho ,sqrt(interim),rho
,1) ,4,4) ##covariance matrix for the 2nd stage test
statistics
s121 <-matrix(c(1,rho ,sqrt(interim),rho ,1,sqrt(interim)*rho
,sqrt(interim),sqrt(interim)*rho ,1) ,3,3) ##
covariance matrix for the 1st stage and one of 2nd
stage test statistics
s122 <-matrix(c(1,rho ,sqrt(interim)*rho ,rho ,1,sqrt(interim)
,sqrt(interim)*rho ,sqrt(interim) ,1) ,3,3) ##
covariance matrix for the 1st stage and one of 2nd
stage test statistics
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solve_c1<-function(c1) 1-pnorm(c1)+1-pnorm(c1*ratio)-
sadmvn(lower=c(c1 ,c1*ratio),upper=c(Inf ,Inf),c(0,0),s1)
-alpha1
c1<-uniroot(solve_c1,interval=c(0 ,100))$root ###given
pi1, get c1’s
solve_c2<-function(c2) sadmvn(lower=c(-Inf ,-Inf ,c2),upper=
c(c1 ,c1*ratio ,Inf),c(0,0,0),s121)+sadmvn(lower=c(-Inf ,-
Inf ,c2*ratio),upper=c(c1,c1*ratio ,Inf),c(0,0,0),s122)-
sadmvn(lower=c(-Inf ,-Inf ,c2 ,c2*ratio),upper=c(c1 ,c1*
ratio ,Inf ,Inf),c(0,0,0,0),s2) -(alpha -alpha1)
c2<-uniroot(solve_c2,interval=c(0 ,100))$root ###get the
solutions for c2’s
output <-c(c1,c1*ratio ,c2,c2*ratio)
return(output) }
##Example of calling the function to calculate the
stopping boundaries
c_values(interim =0.5,rho=0.5, alpha1 =0.0026 , alpha =0.025 ,
ratio =1)
[1] 2.5578 2.5578 2.3279 2.3279
##Stopping boundary for two endpoints is 2.5578 in the
interim analysis of information time as 0.5, and 2.3279
in the final stage.
Appendix H
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Power comparisons of Pocock Boundary
Table H.1: Power comparisons given n = 200, µ2 = 0.2, α = 0.025
and interim time τ = 0.5 (10,000 simulations).
Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Disjunctive Power§
ρ = 0
-0.1
GSMulti 0 0.670 0.670 (0.327+0.343)
GSMulti unbal 0 0.708 0.708 (0.367+0.341)
GSD Pocock 0 0.670 0.670 (0.325+0.344)
GSD Pocock w 0 0.707 0.707 (0.367+0.340)
Tang&Geller 0 0.151 0.152 (0.068+0.084)
0.05
GSMulti 0.048 0.661 0.690 (0.346+0.344)
GSMulti unbal 0.033 0.702 0.720 (0.379+0.341)
GSD Pocock 0.048 0.660 0.690 (0.344+0.346)
GSD Pocock w 0.032 0.701 0.718 (0.379+0.340)
Tang&Geller 0.092 0.592 0.657 (0.337+0.320)
0.1
GSMulti 0.144 0.645 0.729 (0.378+0.350)
GSMulti unbal 0.106 0.69 0.746 (0.403+0.343)
GSD Pocock 0.143 0.644 0.728 (0.376+0.352)
GSD Pocock w 0.106 0.688 0.745 (0.403+0.342)
Tang&Geller 0.260 0.692 0.817 (0.480+0.337)
0.2
GSMulti 0.561 0.552 0.895 (0.556+0.340)
GSMulti unbal 0.491 0.61 0.889 (0.545+0.343)
GSD Pocock 0.561 0.551 0.895 (0.554+0.341)
GSD Pocock w 0.491 0.610 0.888 (0.546+0.342)
Tang&Geller 0.765 0.755 0.969 (0.739+0.231)
ρ = 0.25
-0.1
GSMulti 0 0.673 0.673 (0.329+0.344)
GSMulti unbal 0 0.713 0.713 (0.370+0.344)
GSD Pocock 0 0.671 0.671 (0.325+0.345)
GSD Pocock w 0 0.708 0.708 (0.367+0.341)
Tang&Geller 0 0.130 0.130 (0.060+0.070)
0.05
GSMulti 0.046 0.666 0.685 (0.342+0.343)
GSMulti unbal 0.031 0.708 0.718 (0.376+0.342)
GSD Pocock 0.045 0.664 0.682 (0.338+0.344)
GSD Pocock w 0.030 0.704 0.713 (0.374+0.340)
Tang&Geller 0.093 0.534 0.559 (0.271+0.288)
0.1
GSMulti 0.138 0.653 0.710 (0.366+0.344)
GSMulti unbal 0.101 0.698 0.735 (0.394+0.341)
GSD Pocock 0.137 0.650 0.707 (0.363+0.344)
GSD Pocock w 0.100 0.694 0.730 (0.391+0.339)
Tang&Geller 0.260 0.655 0.723 (0.392+0.331)
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Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Disjunctive Power§
ρ = 0.25 0.2
GSMulti 0.572 0.567 0.865 (0.521+0.344)
GSMulti unbal 0.498 0.625 0.860 (0.515+0.345)
GSD Pocock 0.570 0.565 0.862 (0.517+0.345)
GSD Pocock w 0.496 0.621 0.856 (0.513+0.343)
Tang&Geller 0.760 0.753 0.927 (0.633+0.294)
ρ = 0.5
-0.1
GSMulti 0 0.679 0.679 (0.334+0.346)
GSMulti unbal 0 0.719 0.719 (0.374+0.346)
GSD Pocock 0 0.668 0.668 (0.324+0.344)
GSD Pocock w 0 0.708 0.708 (0.366+0.342)
Tang&Geller 0 0.115 0.115 (0.053+0.062)
0.05
GSMulti 0.043 0.674 0.683 (0.340+0.342)
GSMulti unbal 0.028 0.717 0.720 (0.377+0.344)
GSD Pocock 0.041 0.664 0.672 (0.331+0.341)
GSD Pocock w 0.027 0.706 0.710 (0.369+0.341)
Tang&Geller 0.094 0.476 0.484 (0.229+0.254)
0.1
GSMulti 0.135 0.664 0.697 (0.357+0.341)
GSMulti unbal 0.097 0.711 0.729 (0.387+0.342)
GSD Pocock 0.130 0.654 0.686 (0.347+0.339)
GSD Pocock w 0.092 0.700 0.718 (0.379+0.338)
Tang&Geller 0.261 0.611 0.640 (0.329+0.312)
0.2
GSMulti 0.591 0.583 0.832 (0.490+0.341)
GSMulti unbal 0.511 0.646 0.829 (0.486+0.343)
GSD Pocock 0.583 0.574 0.822 (0.480+0.342)
GSD Pocock w 0.503 0.637 0.820 (0.477+0.343)
Tang&Geller 0.754 0.747 0.874 (0.553+0.321)
ρ = 0.75
-0.1
GSMulti 0 0.696 0.696 (0.352+0.344)
GSMulti unbal 0 0.735 0.735 (0.391+0.343)
GSD Pocock 0 0.673 0.673 (0.328+0.345)
GSD Pocock w 0 0.711 0.711 (0.370+0.340)
Tang&Geller 0 0.107 0.107 (0.049+0.058)
0.05
GSMulti 0.041 0.696 0.697 (0.353+0.344)
GSMulti unbal 0.027 0.734 0.735 (0.392+0.343)
GSD Pocock 0.037 0.672 0.674 (0.329+0.345)
GSD Pocock w 0.023 0.711 0.711 (0.370+0.340)
Tang&Geller 0.095 0.428 0.428 (0.196+0.232)
0.1
GSMulti 0.134 0.692 0.700 (0.359+0.341)
GSMulti unbal 0.093 0.733 0.736 (0.394+0.342)
GSD Pocock 0.122 0.668 0.677 (0.336+0.341)
GSD Pocock w 0.084 0.709 0.712 (0.373+0.339)
Tang&Geller 0.263 0.572 0.577 (0.283+0.294)
0.2
GSMulti 0.627 0.622 0.802 (0.460+0.342)
GSMulti unbal 0.540 0.687 0.798 (0.456+0.342)
GSD Pocock 0.602 0.601 0.780 (0.435+0.345)
GSD Pocock w 0.518 0.666 0.776 (0.434+0.342)
Tang&Geller 0.750 0.749 0.824 (0.485+0.339)
*: pi1 = 0.0144; §: Disjunctive power at the interim + at the final;
GSMulti: c1(τ) = c2(τ), c1(1) = c2(1); GSMulti unbal: c1(τ) = 1.11c2(τ), c1(1) =
1.11c2(1); GSD OBF: α1 = α2; GSD OBF w: 2α1 = α2.
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Table H.2: Power of rejecting both endpoints simultaneously given
n = 200, µ2 = 0.2, α = 0.025 and interim time τ = 0.5 (10,000
simulations).
Correlation µ1 Approach*
Power Power Overall
for E1 for E2 Conjunctive Power†
ρ = 0
0.05
GSD graphic 0.080 0.675 0.065 (0.017+0.047)
GSMulti 0.058 0.670 0.037 (0.009+0.028)
GSMulti v 0.080 0.675 0.065 (0.017+0.048)
0.1
GSD graphic 0.228 0.685 0.185 (0.046+0.139)
GSMulti 0.178 0.670 0.119 (0.023+0.097)
GSMulti v 0.230 0.686 0.187 (0.045+0.141)
0.2
GSD graphic 0.734 0.727 0.566 (0.176+0.390)
GSMulti 0.674 0.670 0.448 (0.104+0.344)
GSMulti v 0.736 0.729 0.569 (0.174+0.395)
ρ = 0.25
0.05
GSD graphic 0.085 0.676 0.079 (0.028+0.051)
GSMulti 0.058 0.673 0.047 (0.015+0.032)
GSMulti v 0.086 0.678 0.080 (0.027+0.053)
0.1
GSD graphic 0.237 0.684 0.214 (0.067+0.147)
GSMulti 0.180 0.673 0.143 (0.037+0.106)
GSMulti v 0.239 0.687 0.216 (0.066+0.151)
0.2
GSD graphic 0.731 0.727 0.596 (0.215+0.382)
GSMulti 0.676 0.673 0.484 (0.143+0.342)
GSMulti v 0.734 0.731 0.600 (0.213+0.387)
ρ = 0.5
0.05
GSD graphic 0.090 0.670 0.088 (0.038+0.050)
GSMulti 0.060 0.679 0.056 (0.022+0.034)
GSMulti v 0.091 0.681 0.089 (0.038+0.052)
0.1
GSD graphic 0.246 0.676 0.236 (0.087+0.149)
GSMulti 0.186 0.679 0.168 (0.054+0.114)
GSMulti v 0.249 0.687 0.239 (0.086+0.152)
0.2
GSD graphic 0.727 0.719 0.624 (0.257+0.368)
GSMulti 0.683 0.679 0.530 (0.184+0.346)
GSMulti v 0.734 0.727 0.630 (0.256+0.374)
ρ = 0.75
0.05
GSD graphic 0.094 0.674 0.094 (0.044+0.049)
GSMulti 0.065 0.696 0.065 (0.031+0.034)
GSMulti v 0.094 0.697 0.094 (0.044+0.050)
0.1
GSD graphic 0.257 0.675 0.255 (0.109+0.147)
GSMulti 0.198 0.696 0.194 (0.076+0.118)
GSMulti v 0.259 0.699 0.258 (0.108+0.150)
0.2
GSD graphic 0.722 0.722 0.664 (0.307+0.357)
GSMulti 0.700 0.696 0.594 (0.247+0.347)
GSMulti v 0.738 0.736 0.673 (0.311+0.362)
pi1 =0.0144;
†: Conjunctive power at the interim analysis + Conjunctive power at the
final analysis;
GSMulti v: GSD with multivariate distribution using reallocating signifi-
cance level.
Appendix I
R function finding µ1 cutoff for better
performance of GSMulti
library(ldbounds)
library(mnormt)
library(gsDesign)
TangGeller <-function(interim ,rho ,u1 ,u2,n,nSims ,alpha ,
alpha1){
set.seed (1234)
n1<-n*interim
##expected mean in the 1st stage
mu11 <-sqrt(n1)*u1
mu12 <-sqrt(n1)*u2
##expected mean in the 2nd stage
mu21 <-sqrt(n)*u1
mu22 <-sqrt(n)*u2
s1=matrix(c(1,rho ,rho ,1) ,2,2)
d<-sqrt(diag(solve(s1)))
stage1 <- rmnorm(nSims , mean=c(mu11 ,mu12),varcov=
s1)
z12 <-apply(stage1 ,1,function(x) t(d)%*%x/sqrt(t(d)
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%*%s1%*%d))
phi_func <-function(phi) bounds(c(interim ,1),iuse
=3,phi=phi ,alpha=alpha)$exit.pr[1]- alpha1
phi <-uniroot(phi_func ,c(0.0000001 ,10))$root
c_s<-bounds(c(interim ,1),iuse=3,phi=phi ,alpha=
alpha)$upper.bounds
stop1 <- ifelse(z12 >=c_s[1],1,0)
stage2 <-rmnorm(nSims ,mean=c(sqrt(n-n1)*u1,sqrt(n-
n1)*u2),varcov=s1)
test_stage2 <-sapply (1:2, function(i) (stage2[,i]*
sqrt(1/(n-n1))*(n-n1)+stage1[,i]*sqrt(1/n1)*n1)
/n*sqrt(n))
z12_2<-apply(test_stage2 ,1,function(x) t(d)%*%x/
sqrt(t(d)%*%s1%*%d))
stop2 <- ifelse(z12_2[stop1 ==0]>= c_s[2],1,0)
reject_multi <-(sum(stop1)+sum(stop2))/nSims
return(reject_multi)}
u1_threshold <-function(interim ,alpha1 ,alpha ,rho ,u2,n){
n1<-n*interim
mu11 <-sqrt(n1)*u1
mu12 <-sqrt(n1)*u2
mu21 <-sqrt(n)*u1
mu22 <-sqrt(n)*u2
find_gsmulti_u1<-function(u1){
s1<-matrix(c(1,rho ,rho ,1) ,2,2)
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s2<-matrix(c(1,rho ,sqrt(interim),sqrt(
interim)*rho ,rho ,1,sqrt(interim)*rho ,
sqrt(interim),sqrt(interim),sqrt(
interim)*rho ,1,rho ,sqrt(interim)*rho ,
sqrt(interim),rho ,1) ,4,4)
s121 <-matrix(c(1,rho ,sqrt(interim),rho ,1,
sqrt(interim)*rho ,sqrt(interim),sqrt(
interim)*rho ,1) ,3,3)
s122 <-matrix(c(1,rho ,sqrt(interim)*rho ,rho
,1,sqrt(interim),sqrt(interim)*rho ,sqrt
(interim) ,1) ,3,3)
solve_c1<-function(c1) 1-pnorm(c1)+1-pnorm
(c1)-sadmvn(lower=c(c1,c1),upper=c(Inf ,
Inf),c(0,0),s1)-alpha1
c1<-uniroot(solve_c1,interval=c(0 ,100))$
root
solve_c2<-function(c2) sadmvn(lower=c(-Inf
,-Inf ,c2),upper=c(c1,c1 ,Inf),c(0,0,0),
s121)+sadmvn(lower=c(-Inf ,-Inf ,c2),
upper=c(c1 ,c1,Inf),c(0,0,0),s122)-
sadmvn(lower=c(-Inf ,-Inf ,c2 ,c2),upper=c
(c1 ,c1,Inf ,Inf),c(0,0,0,0),s2) -(alpha -
alpha1)
c2<-uniroot(solve_c2,interval=c(0 ,100))$
root
power_tg<-TangGeller(interim=interim ,rho=
rho ,alpha1=alpha1 ,alpha=alpha ,u1=u1,u2=
138
u2 ,n=n, nSims =10000)
power_diff <-1-pnorm(c1 ,mu11 ,1)+1-pnorm(c1 ,
mu12 ,1)-sadmvn(lower=c(c1,c1),upper=c(
Inf ,Inf),c(mu11 ,mu12),s1)+sadmvn(lower=
c(-Inf ,-Inf ,c2),upper=c(c1 ,c1,Inf),c(
mu11 ,mu12 ,mu21),s121)+sadmvn(lower=c(-
Inf ,-Inf ,c2),upper=c(c1,c1,Inf),c(mu11 ,
mu12 ,mu22),s122)-sadmvn(lower=c(-Inf ,-
Inf ,c2,c2),upper=c(c1 ,c1,Inf ,Inf),c(
mu11 ,mu12 ,mu21 ,mu22),s2)-power_tg
return(power_diff) }
u1_cutoff <-uniroot(find_gsmulti_u1 ,c(-10,10))$root
return(u1_cutoff)}
##Example to find cutoff of effect size of E1 for which
GSMulti is better than Tang & Geller procedure given
other parameters.
u1_threshold(interim =0.5, alpha1 =0.0014 , alpha =0.025 , rho
=0.75,u2=0.2,n=300)
[1] 0.1512545
##When u1 <0.1512545, GSMulti is recommended given
parameters above.
Appendix J
FWER for DLDGKP using Utility
Function
The dropping arm mechanism of DLDGKP using utility function depends on the
efficacy data, which makes the theoretical proof of strong control in FWER complicated.
To check the FWER for such a design, the simulations with four treatment arms were
conducted. Two configurations of null hypothesis and different toxicity rate response
curve are considered as in Table J.1. From the table, the FWER is well controlled for
the situations that we considered.
Table J.1: Familywise error rate of DLDGKP using utility function
given α = 0.025 (100,000 simulations).
Toxicity Rate µ1 = µ2 = µ1 = µ2 = 0,µ3 = µ4 = 0 µ3 = 0.001, µ4 = 0.01
Zero* 0.024 0.013
Low Flat 0.013 0.007
High Flat 0.001 0.001
Linear 0.011 0.010
Log 0.004 0.004
*: All Four groups have zero toxicity rate.
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